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Abstract 
Osteoarthritis (OA) affects 1 in 10 Canadians and is a leading cause of mobility disability 
worldwide. This condition is characterized by cartilage degeneration, subchondral bone 
damage and inflammation of the synovium, resulting in pain and joint failure. No treatments 
exist to stop the progression of this disease, and its underlying molecular mechanisms remain 
largely unknown. We previously identified the peroxisome proliferator activated receptor 
(PPAR) nuclear receptor pathway as altered in OA cartilage. In-vitro studies identified 
PPARδ as a promoter of catabolic activity in chondrocytes, providing the foundation for my 
overarching hypothesis that PPARδ inhibition is protective in OA. 
I commenced my thesis by generating Ppard cartilage-specific knockout mice to investigate 
the role of this gene in skeletal development. I evaluated the anatomy, morphology, and 
cellular organization of the skeleton, long bones and growth plate through histological 
techniques and concluded that there were no congenital abnormalities predisposing these 
mice to OA. I next compared the progression of disease severity between Ppard KO mice 
and WT controls after destabilization of medial meniscus surgery to induce post-traumatic 
osteoarthritis (PTOA). After histopathological assessment, I found that mice lacking PPARδ 
were significantly protected from cartilage damage and displayed decreased cartilage matrix 
breakdown in lesioned areas.  
Subsequently, I evaluated pharmacological inhibition of PPARδ in PTOA in rats. I 
discovered that PPARδ inhibitors prevent behavioural modifications associated with OA 
development and pain. However, their effects on structural progression of OA remains 
inconclusive and more stringent quantitative methods are needed to assess these differences.  
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Lastly, I examined global gene expression through microarray analysis of chondrocytes 
treated with a PPARδ agonist. I discovered that genes induced were primarily involved in 
lipid metabolism, which translated into functional changes in lipid metabolism, such as 
significantly decreased cellular triglycerides. Mediators of oxidative stress were also 
identified, and Txnip, an inhibitor of anti-oxidant thioredoxin, was significantly elevated in 
response to PPARδ activation. Immunohistochemistry revealed increased TXNIP staining in 
OA cartilage, but substantially less in cartilage of Ppard KO mice.  
Overall, these data demonstrate a novel role for PPARδ in Osteoarthritis. My data support 
my hypothesis that PPARδ inhibition is protective in OA. 
 
Keywords: Peroxisome Proliferator Activated Receptor delta, Osteoarthritis, Articular 
Cartilage, Joint Homeostasis, Transgenic Mice, Skeleton, Synovial Joint 
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Epigraph 
I am among those that think science has great beauty. A scientist in 
[her] laboratory is not only a technician, [she] is also a child confronting 
natural phenomena that will impress [her] as if they were fairy tales.” -
Marie Curie 
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Chapter 1  
1 Introduction 
The severity and impact of musculoskeletal disease is tremendous. As the number one 
cause of ‘years lost to disability’ worldwide, they detrimentally influence both the 
morbidity and mortality of those afflicted[1].  Osteoarthritis (OA) is the most prevalent 
joint disease worldwide, affecting 10% of men and 18% of women over the age of 60[2]. 
Although commonly thought of as a disease of aging, approximately half of all 
individuals diagnosed with arthritis are working age adults[3].  OA places a substantial 
economic burden on countries, annually accounting for approximately $190 billion in 
North American direct and indirect health care costs or between 1.0 and 2.5% of the 
gross domestic product in developed countries[2, 4]. However, we currently have no 
effective treatment to alter the course of disease progression. This condition can affect 
one or more synovial joints but most commonly the knees, hips, hands and facet joints of 
the spine, and the principal symptom of this disease is pain[5, 6]. In this chapter we 
examine the synovial joint, with a special focus on articular cartilage and the crucial link 
between form and function in joint health and the pathogenesis of OA. 
1.1 The Synovial Joint 
Joints facilitate movement and flexibility through interaction between two or more 
skeletal elements[7]. Synovial joints are comprised of two opposing long bones, the ends 
of which are covered in articular cartilage. The bones provide structure and strength 
while the cartilage is responsible for receiving and dissipating loads associated with 
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weight-bearing. The joint is enclosed by a fibrous capsule, the joint capsule, which is 
lined by synovium. Synovium is the defining feature of the literally monikered synovial 
joint; it produces synovial fluid which enables frictionless movement, and also helps 
deliver nutrients and remove waste from the cartilage[8, 9]. Supporting structures include 
ligaments which confer stability and maintain proper alignment, and muscles which 
enable movement. Additionally, some joints have menisci, fibrocartilaginous pads, which 
further contribute to shock absorption[10]. Together these tissues act synchronously to 
stabilize the joint, distribute loads and permit frictionless movement. An example of a 
healthy synovial joint is shown in Figure 1-1.  
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Figure 1-1 Synovial joint in health and OA 
The synovial joint is comprised of opposing long bones, the ends of which are covered in 
articular cartilage. The cartilage and bone act in concert to receive and dissipate loads 
associated with movement and weight bearing. The joint is enclosed by the joint capsule 
and lined with a semipermeable membrane; the synovium. The synovium produces 
synovial fluid which fills the joint cavity, lubricating the joint. Ligaments and 
musculature confer stability, and ensure joint alignment. Figure courtesy of Dr. M. Pest. 
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1.2 Cartilage 
Cartilage is a dense connective tissue, whose function is varied and dependent on its 
composition, mechanical and biochemical environment[11]. The relative proportion and 
organization of collagen fibers that form its extracellular matrix determine whether it is 
elastic, hyaline or fibrocartilage. Elastic cartilage is characterized by collagen 1 and, as 
the name suggests, elastin fibers. This type of cartilage is commonly found in the ear, and 
epiglottis. Fibrocartilage is also predominantly composed of collagen 1, and this type of 
cartilage is located in the intervertebral discs of the spine as well as in the menisci of 
many synovial joints[12]. Comparatively, hyaline cartilage is principally composed of 
collagen 2 and is found in growth plate and articulating surfaces of long bones[13].  
1.2.1 Articular Cartilage Composition 
Articular cartilage is a type of hyaline cartilage located at the articulating surfaces of long 
bones in synovial joints. It is both avascular and aneural, and functions to provide a 
frictionless, shock-absorbing surface to aid mobility and load bearing[14-16]. 
Chondrocytes are the sole cell type of hyaline cartilage, originating from mesenchymal 
stem cells. They vary in size and shape and distribution depending on the region of 
cartilage they are located in. Although they make up only 2% of cartilage in human 
articular cartilage, they function to produce and maintain the health of cartilage by 
regulating extracellular matrix (ECM) turnover[11, 17]. The ECM of cartilage is 
comprised of a fluid and a macromolecular component. A specialized matrix comprised 
predominantly of collagen and of aggregate proteoglycans forms the framework 
responsible for the structural integrity of the tissue. Other molecules such as lipids, 
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phospholipids, glycoproteins and non-collagen ECM proteins are present in smaller 
amounts. The fluid component of the ECM consists of water, cations and gases and small 
electrolytes. In fact, 70-80% of the mass of human articular cartilage is water[18-20].  
Aggrecan is the principal proteoglycan in cartilage, and is made up of a core protein with 
glycosaminoglycan (GAG) side-chains. In aggrecan, these sidechains are chondroitin 
sulfate (majority) and keratan sulfate (minority). Perlecan, decorin and biglycan are 
additional proteoglycans found in the cartilage matrix[21]. The GAG sidechains are 
negatively charged, and this attribute is what enables the most distinguishing 
characteristic of cartilage; its unique ability to attract and trap water[22]. In articular 
cartilage, aggrecan, hyaluronic acid (HA) and link protein form non-covalently associated 
large aggregate complexes which exponentially enhance this attribute[19, 23]. Collagen 2 
is the predominant collagen in cartilage and forms the filamentous ultrastructure of the 
ECM. The organization and distribution of Collagen 2 throughout the matrix is 
responsible for the tensile stiffness and for restricting tissue deformity when swelling 
proteoglycan aggregates trap water. Other collagens in articular cartilage include type IX 
and type XI which are associated with collagen II fibrils [24, 25]. 
1.2.2 Zonal and Regional Organization of Cartilage 
Articular cartilage can be divided into four zones. Each of the zones has differentially 
organized cells, proteoglycans and collagen fibrils that influence its specific function. 
The zones of cartilage include: 1) superficial zone; 2) middle zone; 3) deep zone; 4) 
calcified cartilage, as depicted in Figure 1-2. Chondrocytes of the superficial zone (SZ) 
that borders the synovial space are flattened, with tightly packed collagen fibrils that are  
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oriented tangential to the surface. As the thinnest zone, the SZ has the lowest 
concentration of proteoglycans, and the highest concentration of water[11, 16]. Mid Zone 
(MZ) chondrocytes are more spherical, and as depth progresses from the mid zone (MZ) 
to the deep zone (DZ) the concentration of proteoglycan increases. Cartilage cells in the 
deep zone synthesize the most proteoglycans and are arranged in columns[26]. Collagen 
fibrils in the MZ are uniformly dispersed and randomly oriented, and become thicker and 
perpendicularly arranged to the joint surface in the DZ[27]. The tidemark, a histologically 
visible line, forms the boundary between the uncalcified and calcified cartilage. It is here 
that collagen bundles form an interlocking network that strongly anchors the overlying 
uncalcified cartilage to the calcified cartilage below[19, 28]. 
Articular cartilage ECM is also regionally organized. While zones are stratified based on 
depth from surface, regional organization is determined by distance from the 
chondrocyte. The region in closest proximity to the chondrocyte is the pericellular matrix, 
which fully envelopes the chondrocyte forming a unit called a chondron. The chondron is 
very dense in proteoglycans, contains non-collagenous proteins and contributes to signal 
transduction in response to mechanical stimulation[11, 16, 17].  The territorial matrix 
surrounds individual chondrons, clusters or columns of chondrons, forming a basketlike 
network of fibrils, and is thought to help protect chondrocytes from deformations 
associated with loading. Lastly, the interterritorial matrix is the largest and farthest away 
from the chondrocyte and consists of a network of collagen fibrils that confers tensile 
strength to the cartilage[29]. 
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Figure 1-2 Zonal organization of articular cartilage 
Articular cartilage is organized into four zones with distinct organization, composition 
and function. 1) The SZ possesses the greatest water content and collagen 2 fibril density. 
Collagen fibrils are oriented tangentially, and proteoglycan density is lowest. 
Chondrocytes are small and flattened. 2) The MZ has less water content than the 
superficial zone and collagen 2, but has greater proteoglycan density than the SZ. 
Collagen fibers are heterogeneously dispersed and randomly oriented. Chondrocytes are 
spherical. 3) The DZ has greatest proteoglycan content, but the lowest water 
concentration and collagen content. Collagen fibers are radially oriented and are thickest 
here. Chondrocytes are oriented in clusters, and have larger volumes. 4) The calcified 
cartilage is closest to the bone and separated from the DZ by the tidemark. 
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1.2.3 Biomechanical Properties of Cartilage 
It has been established that each chondrocyte produces the matrix surrounding itself, and 
thus creates its own microenvironment. In turn, the cell is trapped by the matrix; the very 
environment it has established[17]. This can be beneficial as the surrounding matrix 
shields the cell from forces which act to deform the shape of the cartilage during weight-
bearing and movement (as discussed above). Consequentially, there is very little direct 
cell to cell communication in healthy articular cartilage. On the other hand, chondrocytes 
are extremely interactive with their microenvironment and respond to growth factors, 
mechanical loads, piezoelectric forces, hydrostatic pressure and, as we will discuss later, 
lipids[30].  
Although cartilage is 70-85% water, the distribution of this water content varies 
according to the depth of cartilage. The fluid content is the greatest for the upper 25% of 
cartilage and drops as depth increases[31]. The composition and zonal organization of the 
cartilage is essential to its role distributing stresses associated with load bearing. When a 
force is applied, cartilage on opposing sides of the joint are pushed towards each other 
and this initial force causes a rapid and immediate increase in fluid pressure in the 
joint[32]. The increase in fluid pressure squeezes the fluid out of the contact area in the 
solid matrix[33]. However, frictional resistance against this flow is very high and 
permeability of the cartilage is low. As fluid is forced out of the matrix, it becomes less 
porous, thereby decreasing permeability and preventing water leaving from deeper 
regions of the cartilage[11, 34].  Additionally, areas of cartilage adjacent to the contact 
stress are also pressurized, while the subchondral bone underneath the cartilage is 
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impervious to fluid flow[31, 35]. The combination of these properties limit the extent of 
deformation of the cartilage and is the reason why cartilage is capable of withstanding 
substantial loads.  
1.2.4 Biochemical and Metabolic Properties of Cartilage 
The composition and porous structure of articular cartilage is not only important for 
loading, but also necessary to facilitate nutrient transport because cartilage lacks 
innervation from blood and lymphatic vessels. Thus chondrocytes must either receive 
nutrients from the synovial fluid or from diffusion from the subchondral bone below[36, 
37]. Although adult articular cartilage is relatively metabolically inactive and the turnover 
rate for matrix components is quite low, matrix synthesis is an energy intensive process 
and chondrocytes rely heavily on energy stores and ATP production[38, 39]. Anaerobic 
glycolysis is primarily used by the cell since oxygen levels are low due to the lack of 
blood supply, and up to 80% of glucose is metabolized to lactate[40]. The chondrocyte 
expresses both GLUT1 (Glucose transporter 1) and GLUT3 (Glucose transporter 3) 
transporters to facilitate the movement of glucose into the cell, and lactic acid 
transporters MCT4 (monocarboxylate 4) and MCT 1 (monocarboxylate 1) to efflux lactic 
acid from the cell[41-43]. There is evidence that the TCA cycle is used, and that 
oxidative phosphorylation occurs, but this accounts for less than 10% of normal 
chondrocyte energy metabolism[40, 43]. 
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1.2.5 Molecular Regulation of Extracellular Matrix Turnover 
In healthy cartilage, a balance between ECM synthesis and degradation maintains 
homeostasis. The half life of aggrecan is approximately 24 years while the half life of 
collagen II is more than 100 years in articular cartilage; thus, turnover of matrix is 
exceptionally slow[44]. Genes encoding matrix proteins such Aggrecan (Acan) and 
Collagen 2 (Col2a1) are directly regulated by the cartilage ‘master’ transcription factor 
Sex- determining- region-Y Box 9 (Sox9). Other cartilage matrix components such as 
biglycan, decorin, cartilage oligomatrix protein, and matrilins also exhibit very low 
turnover. Genes encoding proteases that degrade the matrix such as Matrix 
Metalloproteinases (Mmps), as well as A Disintegrin and Metalloproteinase with 
Thrompospondin Motifs 4, 5 (Adamts4, Adamts5), are active at low levels to break down  
damaged collagen II and aggrecan, respectively[45].  
1.3 Bone 
One might say it is humerus that the bone performs so many functions including the 
protection of vital organs, locomotion through transmission of loads and serving as an 
anchor for muscle attachment, the maintenance of systemic calcium and phosphate 
mineral homeostasis, as well as a providing the environment for hematopoietic and 
mesenchymal stem cells[46, 47]. Bone cells, like cartilage cells, synthesize an ECM 
whose organization is paramount to its function. It can be divided into organic and 
inorganic components. Collagen 1 is the principal component of the organic portion, and 
it is organized in parallel layers which confer both tensile strength and flexibility. The 
collagen fibrils act as a framework for the hydroxyapatite crystals [Ca10(PO4)6(OH)2], 
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that form the inorganic portion of bone and pack tightly around this framework to provide 
structural support against compressive loading[48].  
ECM maintenance in bone is regulated by osteoblasts and osteoclasts. Osteoblasts, or 
bone forming cells, are responsible for the synthesis of matrix constituents such as 
Collagen 1, non-collagenous proteins (such as osteocalcin, biglycan, bone sialoprotein 
etc.), and the osteoid that eventually becomes mineralized to form the calcified bone 
matrix[49, 50]. Like cartilage cells they are derived from mesenchymal stem cells, and 
differentiation to this lineage is regulated by runt-related transcription factor, Runx2. A 
portion of the osteoblasts become trapped within the osteoid, and are then called 
osteocytes. These cells still function to produce necessary proteins and signal to recruit 
osteoclasts when the matrix is damaged, or bone remodeling is required[51]. Osteoclasts 
are cells that resorb bone matrix and subsequently recruit osteoblasts to ensure structural 
integrity of the structure. They are derived from mononuclear cells. Unlike cartilage, 
bone matrix has a higher turnover rate[52]. 
1.3.1 The role of subchondral bone in the synovial joint 
The primary roles of subchondral bone within the joint is to dissipate the load and 
distribute the strain associated with weight bearing, thus protecting articular cartilage 
against damage caused by excessive loading. It also functions to provide nutrients to the 
overlying cartilage by diffusion through the calcified cartilage matrix. The subchondral 
bone region is highly vascularized and innervated, and helps supply cartilage with 
oxygen, water and glucose[53].  
12 
 
The articular cartilage, which is zonally organized, becomes more stiff as the uncalcified 
cartilage transitions to calcified cartilage and then subchondral bone. While many 
collagen 2 fibrils lock the uncalcified cartilage to the calcified layer beneath, there are no 
such connections between the calcified cartilage and underlying bone[54]. Therefore, to 
adequately transmit shear forces, the calcified cartilage has a jagged boundary in which it 
fits into the subchondral bone like a “jigsaw puzzle” in order to lock in into place. In fact, 
the majority of force transmitted through the joint is absorbed by the subchondral bone, 
even though healthy articular cartilage can withstand 2.5-5 times the peak deformation 
caused by walking (which is roughly equal to several times one’s body weight)[53, 55, 
56]. Accordingly, bone and cartilage must work in unison to enable frictionless 
movement and transmit loads effectively. 
1.4 Synovium and Synovial Fluid 
The joint capsule acts as a barrier from the rest of the body by encapsulating the joint. 
The interior of the joint capsule is lined with synovium; a selectively permeable 
membrane that filters blood plasma to form an ultra-filtrate[57]. This filtrate is combined 
with lubricating molecules such as lubricin and hyaluronan to form synovial fluid (SF).  
Superficial zone chondrocytes produce lubricin, while synoviocytes (highly metabolically 
active cells lining the synovium) produce both lubricin and hyaluronan[15, 58]. SF is a 
viscous fluid, and its primary role is as a lubricant in the joint to enable frictionless 
movement with minimal wear to other joint tissues[9, 36, 57-59]. It also facilitates the 
exchange of nutrients and wastes between the cartilage, synovium and plasma, and 
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contains soluble molecules such as growth factors, and cytokines to mediate 
communication between different cell populations within the joint[59]. 
1.5 Supporting Structures of the Joint 
Muscle and ligaments are also integral components of the joint and serve to confer 
stability and maintain joint alignment during ambulation. Appropriate skeletal muscle 
contraction and nerve control is necessary to perform accurate and controlled 
movement[60, 61]. Ligaments are responsible for joint alignment which ensures forces 
are distributed correctly over the joint surface[62]. Some joints have menisci, 
fibrocartilaginous pads composed of meniscal cells, an ECM which is mostly type I 
collagen, and water which makes up 70% of the structure by weight. Menisci play a 
crucial role in shock absorption within the knee, wrist, jaw and collar bone joints[63].  
1.6 Etiology of Osteoarthritis 
OA is a heterogenous, multifactorial condition that can affect multiple joints, and the 
severity of pain and loss of function are variable between patients[64, 65]. It is the 
leading cause of mobility disability worldwide[66, 67]. It is characterized by the 
progressive breakdown of articular cartilage, subchondral bone changes, and synovial 
hyperplasia.  OA primarily targets weight-bearing joints and can make even routine self-
care tasks extremely difficult. The molecular mechanisms responsible for this condition 
are not well understood and therefore no treatments exist to halt or delay the progression 
of the disease. The exact etiology of OA is unknown, but factors which promote the 
progression of this condition have been and continue to be extensively studied. 
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1.6.1 Classification  
Osteoarthritis is conventionally classified as primary or secondary OA. Primary OA is 
idiopathic, and stems from no discernible cause. It is commonly referred to as age 
associated OA, and rarely occurs in individuals less than 40 years of age[68]. Secondary 
OA develops is attributable to a specific cause. This includes joint trauma, hereditary, 
metabolic, mechanical reasons as well as diseases that affect joint alignment or 
biochemical tissue composition[69].  In many cases, individuals with primary OA have 
some genetic susceptibility or predisposition to it, and there is no clear distinction 
between the two[70]. 
1.6.2 Risk Factors 
Risk factors that increase the probability of developing OA are described below and 
shown in Figure 1-3. It should be noted that these risk factors are not mutually exclusive, 
and that individuals can possess more than one risk factor. It has also been demonstrated 
that the progression of OA varies significantly between individuals; some joints remain 
radiographically stable while others deteriorate rapidly. 
1.6.2.1 Age and Gender 
Age is the strongest, most predictive risk factor for OA affecting the hip, knee, and 
hands[71-74]. The effects of other factors such as obesity, ligament laxity, sarcopenia, 
and impaired proprioception are compounded with age, and may contribute to increased 
load or abnormal loading of the joint[75]. Aging decreases reparative responses in the  
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Figure 1-3 Risk factors for osteoarthritis 
Risk factors which increase individuals’ susceptibility to OA are shown above. Age, 
female gender, hereditary factors, joint injury, obesity (metabolic factors), and overuse 
(mechanical factors) all increase likelihood of OA development. 
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joint, and joint injury can be especially detrimental with older patients demonstrating 
progressive changes more quickly[76, 77]. 
The incidence of polyarticular, hand and knee OA is increased in females, and so are 
symptoms of OA such as pain, and decreased physical function[75, 78, 79]. Interestingly, 
women also have increased rates of cartilage loss and structural OA progression though 
reasons for this remain inconclusive[80]. 
1.6.2.2 Hereditary Factors 
Hereditary factors represent another unmodifiable risk factor for OA progression. There 
are multiple genes that have been implicated in OA susceptibility, and their 
predisposition in combination with environmental factors cannot be ignored. Twin 
studies have shown that heritability of hand, knee and hip OA to be 40-60% in 
women[81, 82]. Mutations in genes associated with rare skeletal malformation disorders 
contribute to the pathogenesis of OA, through anatomical changes in joint shape or tissue 
integrity which influence joint mechanics[83]. Current studies suggest that because OA is 
genetically heterogeneous, each individual common gene variant only contributes 
modestly to the risk of developing OA[84]. The most consistent and reproducible genetic 
association with OA development has been Gdf5 (growth and differentiation factor 5), a 
member of the TGF-β superfamily[85-87]. This gene is involved in ECM signaling, and 
plays an essential role in development, maintenance and repair of bone, and cartilage[88]. 
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1.6.2.3 Metabolic Factors 
Metabolic OA, has recently been defined as a type of secondary OA. It was long believed 
that obesity contributed to the progression of OA only through mechanical overload in 
the joint. This concept has since been poignantly opposed through stringently peer-
reviewed articles such as “Metabolic factors in osteoarthritis: obese people do not walk 
on their hands”[89]. Presently, it is the second most frequent subtype of OA, and can 
arise from several systemic changes contributing to the pathogenesis of this disease[90, 
91]. Epidemiologically, obesity and adiposity are associated with increased rate of knee 
cartilage volume loss, and the risk of primary knee and hip joint replacement due to OA 
is correlated with fat mass[92, 93]. Adipokines such as leptin are upregulated in 
osteoarthritic cartilage and osteophytes from OA patients[94]. Increased levels of 
products of lipid peroxidation have also been found in joints of OA patients, while levels 
of total fatty acids and arachidonic acid are significantly elevated in OA and correlated 
with histological severity of disease[95-97]. Several prominent studies suggest that 
weight loss, specifically fat loss, greatly improves symptoms in patients[98, 99]. 
1.6.2.4 Anatomical and Mechanical Factors 
Morphology affects how the tissues of the joint accept and distribute load. Consequently, 
a loss of joint congruity can influence susceptibility to OA[100]. Impingement of the hip 
joint, malalignment of the femur and tibia of the knee resulting in ‘bow-legged’ or 
‘knock-kneed’ phenotypes (varus and valgus, respectively), and differential lower limb 
lengths can all increase OA susceptibility[101-104].  Mechanical factors influencing the 
likelihood of OA development include excessive use of the joint, and overloading of the 
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joint, while unloading the joint (such as bed rest) can also lead to atrophy of joint 
tissues[105-107]. 
1.6.2.5 Joint Trauma 
Post-traumatic OA affects 12% of North American OA patients[108], and arises from an 
initial insult to the joint, such as sports injuries, falls, or any condition that destabilizes 
the joint architecture[83, 109, 110]. Most often this involves torn or damaged ligaments 
or menisci; 40% of men, and 50% of women under the age of 40 who had an ACL injury 
developed post-traumatic OA[62, 111]. Other injuries include intraarticular fractures and 
micro-fractures of the subchondral bone[77].  Joint trauma not only induces deleterious 
changes through altered mechanics, but also increased inflammation, and inappropriate 
reparative responses which can lead to further joint damage[77]. 
1.7 Diagnosis 
Pain is most often the reason why individuals seek medical attention, and the 
combination of pain frequency (days of the month) with structural changes assessed 
through radiography are most commonly used to diagnose OA[112-114]. Radiographic 
structural pathology includes joint space narrowing, presence of osteophytes, subchondral 
bone cysts and abnormal joint congruity[115]. Patients may also present with joint 
stiffness, ligament laxity, and synovial inflammation or distention[116]. More recently, 
MRI has been used in research settings due to its ability to clearly distinguish between 
cartilage, menisci and ligaments in contrast to radiographs which cannot differentiate 
between non-ossified tissues[117]. It enables a three dimensional comprehensive view of 
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the joint, and the patient is not subjected to ionizing radiation. However, the clinician 
may perform scoring through WORMS (whole-organ MRI scoring), a comprehensive 
semi-quantitative system that assigns pathological scores to each of the joint tissues[118]. 
While this presents a good alternative to traditional radiography, further validation and 
refinement of the scoring system is needed. Currently, there are no established, validated 
biomarkers predictive of OA but biomarkers indicative of ECM breakdown such as 
(CTX-II, Col2-1, C2C and C2M) may be used as objective tools to evaluate the efficacy 
of interventions[119].  
1.8 Treatment 
There are no current treatments available to ‘cure’ osteoarthritis, or alter the course of 
disease progression. Current therapy modalities treat symptoms such as pain and 
inflammation; they can be classified as life-style centric, medical or surgical. Lifestyle 
interventions include patient education, diet, weight-loss and physical therapy[120]. 
Formerly recommended therapies such as glucosamine and chondroitin sulfate 
supplements, arthroscopies and debridement are advised against as clinical trials have not 
demonstrated benefits[120]. Medical symptomatic relief options include 
viscosupplementation, steroids, analgesics and non-steroidal anti-inflammatory drugs 
(NSAIDs) but this is often not enough, and chronic pain is one of the reasons that most 
patients choose to undergo end-stage joint replacement surgery[5, 121].  End-stage OA is 
treated through prosthetic joint replacement surgery that carries inherent medical risks, 
and patients may need multiple joint replacements and subsequent rehabilitation over the 
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course of their lifetime[122-127]. Moreover, all these approaches are directed at 
symptom management and do not address underlying causes. 
1.9 Pathophysiology of Osteoarthritis 
Osteoarthritis develops when tissue integrity of one or more joint structures is 
compromised. Each of these structures is integral to the whole joint, and a failure of one 
will result in failure of the entire joint (Figure 1-1). 
1.9.1 Pain 
Pain can be categorized as either physiological or pathological pain. Physiological pain is 
acute, presents a normal response to a stimulus (mechanical, thermal, chemical), and 
occurs at a threshold where the stimulus can become physiologically harmful[128]. For 
example; eliciting a withdrawal response for touching a hot stove. Pathological pain, 
commonly referred to as chronic pain, stems from damage to the nervous system or as an 
inflammatory response subsequent to a significant tissue injury. This type of pain can 
occur in the absence of any stimulus, can be amplified in severity or duration, and the 
threshold for eliciting pain is decreased to the point where normally non-painful stimuli 
elicit a pain response (allodynia)[128]. OA pain can be characterized as pathologic pain. 
It is important to note that a significant proportion of individuals that have radiographic 
joint damage do not experience pain and are considered asymptomatic[129]. Although 
cartilage breakdown may be one of the first steps in OA progression, this tissue is both 
aneural and incapable of generating pain directly[130]. The joint capsule, synovium, 
ligaments, subchondral bone and surrounding muscle are all richly innervated; in addition 
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to post-ganglionic sympathetic efferent fibers, they also have a number of sensory 
afferent fibers (proprioceptive and nociceptive)[131]. Thus, nociceptive input from the 
joint can be processed through central and peripheral pathways.  
 
Under pathological conditions such as OA, inflammatory mediators are released into the 
joint and sensitize the nociceptors to mechanical stimuli so they are more likely to 
respond to any stimulus[132]. Cytokines including IL-1β are expressed in peripheral 
blood leukocytes and are associated with increased pain and OA progression[132]. 
Persistent inflammation can also trigger hyper-excitability, an exaggerated response to 
previously innocuous stimuli. Joint neurons can also exhibit primary and secondary 
hyperalgesia, increased responses to stimuli applied to regions close to the joint (for 
example periarticular muscle) and at a distance from the joint (such as in the lower limb 
muscles)[133, 134]. Other cytokines such as TNF-α and IL-6 are elevated during these 
stages and work as pro-nociceptive mediators by directly acting on nociceptive neurons 
that express receptors for these cytokines[135]. Imaging studies of the knee joint have 
shown a correlation between pain, inflammation in the synovium and changes in 
subchondral bone in symptomatic OA, indicating these tissues are reactive and 
responsive in pain pathogenesis[136, 137].  
 
Continued pathological neuronal input such as in advanced OA, can lead to central 
sensitization, changes within the brain and spinal cord that affect the properties of 
sensory neurons wherein they elicit a pain response for non-provoking stimuli.  These 
patients report pain widespread from the site of OA, and demonstrate lower pain 
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thresholds for the entire leg[138, 139].  
 
Nerve growth factor (NGF) is a neuropeptide necessary for the development and 
continued functionality of nociceptors[140]. At sites of inflammation several cell types 
including the chondrocytes and synovial cells produce NGF that has been shown to 
induce hyperalgesia in vivo[141-143]. In humans with moderate to late stage OA, 
injections of Tenazumab (a monoclonal antibody against NGF), provided prolonged pain 
relief and improved function. However, some patients presented with osteonecrosis and 
required total joint replacements[144]. 
1.9.2 Supporting Structures 
Muscle weakness can act as both a risk factor for osteoarthritis (described earlier) but 
also as a consequence of OA. From a pathological perspective, OA can affect muscles 
through hyperalgesia due to central sensitization[145]. Disuse atrophy is common in 
many joints including the hips, knees and ankles[146-150]. It can reduce motor neuron 
excitability, decreasing voluntary muscle activation and proprioception. This reduces 
stability around the joint as well as ability to execute movement[151].  
Menisci from OA patients display morphological changes such as calcium deposition, 
fibrillations, tears and scar tissue[152]. Macroscopic changes have been investigated in 
lapine menisci where the ECM has fine fibrillations, cyst like cavities, and irregular 
proteoglycan staining, as well as a loss of cellular organization, with clusters of cells is 
common [153, 154]. Advanced stages of meniscus degeneration stain intensely and 
positively for the aggrecan breakdown product NITGE[155]. 
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1.9.3 Synovium 
Synovitis is a common feature throughout OA with different types of synovitis associated 
with disease progression. Hyperplasia of the synovial lining is characteristic of early OA, 
while later stages are mainly characterized by capsular fibrosis and accumulation of 
breakdown products of bone and cartilage in the SF[156].  Later stages of radiographic 
OA are also associated with a greater presence of synovitis, with 83% of patients with 
late stage OA presenting with synovitis, versus 38% of those with early OA[157]. OA 
synoviocytes produce less lubricin, and hyaluronan so the composition and viscosity of 
SF is affected along with the joints ability to execute frictionless movement[158, 159]. 
Inflammation and hyperplasia also adversely affect the permeability of the synovial 
membrane which then permits hyaluronan to escape the joint[160].   
Injury to the joint, increased permeability, and damage to the cartilage ECM also activate 
the complement system that responds by formation of the membrane attack complex 
(MAC) on chondrocytes. MAC is comprised of complement effectors C5b-9, and 
formation can result in chondrocyte death or production of matrix degrading 
enzymes[161]. Elevated levels of complement proteins are found in synovial fluid of OA 
patients[162]. ECM damage also increases the expression of TLRs (toll-like receptors) in 
the synovium. Toll-like receptors can stimulate NFkB activation which in turn stimulates 
the production of cytokines and chemokines[163]. These inflammatory mediators then 
perpetuate the feedback loop with cartilage and synovium. 
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1.9.4 Subchondral Bone 
During the course of OA, the composition and structure of the cortical subchondral bone 
plate and the underlying trabecular bone changes, directly affecting the ability of the bone 
to support load and indirectly affecting the overlying articular cartilage[164]. Trabecular 
bone volume increases by approximately 20%, and there is an increase in bone turnover. 
However, the newly formed bone is hypomineralized so it does not confer the same 
stiffness[165-167].  
In concert with changes in composition, bony spurs called osteophytes are formed at joint 
margins. The osteophytes are a hallmark feature of OA and can even be observed prior to 
join space narrowing radiographically[168]. Osteophytes are derived from mesenchymal 
stem cells in the periosteum or the synovial membrane[168]. TGF-β and BMP2 (Bone 
Morphogenetic Protein 2) are anabolic factors believed to be key mediators in the 
formation of osteophytes; under their influence, precursor cells first differentiate into 
chondrocytes, deposit an ECM, undergo hypertrophy and orchestrate bone 
formation[169]. Functionally, osteophytes contribute to pain and limit joint 
mobility[170]. 
The tidemark, known as the demarcation between uncalcified and calcified cartilage 
(Figure 1-2), advances during OA and moves further into the uncalcified cartilage[171]. 
This thins the overlying articular cartilage. It is believed that proangiogenic factors are 
released from DZ chondrocytes undergoing hypertrophy and recruit factors to initiate 
local remodeling.[171, 172]. This contributes to increased stiffness in the articular 
cartilage, and decreases its ability to deform and distribute load[173]. Microfractures can 
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also occur in the zone of calcified cartilage or subchondral trabeculae. The cracks formed 
by these fractures enables the influx of synovial fluid into the zone of calcified cartilage 
and subchondral bone and formation of bone cysts[174]. Bone marrow lesions can also 
form during the pathogenesis of OA, and the location of these lesions corresponds to 
focal articular cartilage defects[175]. When the articular cartilage is completely eroded, a 
loss of joint congruity occurs concurrently with fracturing of the subchondral bone plate 
and sclerosis which in turn can cause the bone to collapse, further offsetting 
congruity[176]. 
1.10 Cartilage in Osteoarthritis 
Adult articular cartilage is a relatively quiescent tissue maintaining ECM homeostasis, 
but in OA this balance is disrupted with a shift towards tissue catabolism[177]. During 
the pathogenesis of OA, cartilage becomes progressively fibrillated and eroded, 
destroying its ability to receive and dissipate loads and rendering it functionally inept. 
Although the etiology of what initiates these events remains unknown, initial responses to 
OA involve upregulation of genes involved in matrix breakdown by chondrocytes, likely 
in order to remodel the damaged ECM. IL-1β and TNF-α are upregulated and increase 
the synthesis of matrix metalloproteinases (1,3 and 13) which are primarily collagenases, 
but also capable of cleaving aggrecan[64, 178]. These inflammatory mediators also act to 
decrease the expression of TIMP (tissue inhibitor of metalloproteinases) proteins. On the 
other hand, upregulation of anabolic genes such as those encoding TGF-β, BMPs, IGF-1 
(Insulin like growth factor 1), and FGFs (Fibroblast Growth Factor) promotes synthesis 
of extracellular matrix. However, there is greater tissue catabolism than anabolism, and 
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this changes the properties of the ECM. The chondrocytes are sensitive to their 
microenvironment. In response to this environment, they can differentiate to a 
hypertrophic phenotype, dedifferentiate to a fibroblast-like cell type, and undergo 
apoptosis[179]. Cellular disorganization is also observed with chondrocyte clustering as a 
result of cell proliferation[65, 180]. 
Possible mechanisms to initiate these changes in chondrocytes include increases in ROS 
(reactive oxidative species) in chondrocytes which can result in mitochondrial 
dysfunction and reduced autophagy [181]. Additionally, the accumulation of cartilage 
matrix proteins that have been modified by oxidative stress in the endoplasmic reticulum 
and golgi apparatus can also decreased ECM synthesis, and cell death[18, 182, 183].  
Oxidative stress and ageing can also increase the accumulation of advanced glycation 
end-products (AGEs) in cartilage. Crosslinking of Collagen 2 by these products can 
increase the stiffness of the cartilage, changing its functional properties[184]. 
Furthermore, elevated levels of ROS and ageing can trigger cellular senescence which 
can trigger a DNA damage response, influencing the cell to stop proliferating and 
increase expression of proinflammatory cytokines and degradative enzymes[185, 186]. 
Phenotypically, the upregulation of anabolic factors can result in the formation of 
osteophytes as the cartilage incorrectly attempts to repair itself. The increase in 
degradative enzymes, particularly ADAM-TS 4,5 and MMP-13, results in the breakdown 
of aggrecan and Collagen 2 and degeneration of the ECM[187-189]. Aggrecan 
breakdown precedes Collagen 2 breakdown in OA, and further exacerbates it[190]. 
Decreased levels of functional aggrecan results in failure of the remaining cartilage to 
accept loads properly, making it even more vulnerable to structural damage.  Cartilage 
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ECM fragments, such as those of fibronectin, can induce the expression of MMPs in 
chondrocytes, further perpetuating cartilage degradation[191].  In addition, cartilage 
detritus can activate TLRs and the complement system in the synovium which, causing 
the release of more inflammatory mediators and degradative enzymes[68, 156]. TLRs 
identified in chondrocyte can also be activated by endogenous products of cellular stress 
or matrix breakdown, and it has been observed that TLR-2 and 4 signals can mediate 
catabolic responses by increasing the expression of MMPs in mouse cartilage[161, 192]. 
In particular, aggrecan breakdown product 32-mer, can act as a ligand for TLR-2. 
However, despite accumulation of knowledge of specific molecular and cellular events 
involved in OA, we still lack many parts of the complete picture, for example on gene 
regulator mechanisms connecting external stimuli to chondrocyte responses.  The nuclear 
receptor family could play a crucial role in this context. 
1.11 Nuclear Receptors 
Nuclear receptors are transcription factors that are regulated by lipophilic small molecule 
ligands, where upon ligand binding they regulate the transcription of their target 
genes[193]. They are comprised of an NH2 terminal domain which houses the ligand 
independent transcriptional activator, AF-1 (Activating Function 1). The DNA binding 
domain (DBD) which contains two highly conserved zinc-finger motifs that recognize 
and bind to specific sequences of DNA termed hormone response elements. The hinge 
region connects the DBD with the LBD (ligand binding domain), and the LBD consists 
of folded alpha helices that contain AF-2 (Activating Function-2) which is responsible for 
ligand dependent transcriptional effects. When a ligand binds to the LBD it induces a 
conformational change which results in the recruitment of co-activators, dissociation of 
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co-repressors promoting transcription of target genes. Nuclear receptors can be divided 
into 4 classes[194]. Class I nuclear receptors exist as homodimers and are usually found 
in the cytosol bound to heat shock proteins. Upon ligand binding they dissociate from 
these proteins and translocate to the nucleus where they bind to the hormone response 
elements that are inverted repeat sequences. Class I nuclear receptors are typically steroid 
hormones such the estrogen, androgen, glucocorticoid and progesterone receptors. Class 
II receptors are typically found in the nucleus bound to the DNA, they usually exist as 
heterodimers (with RXR, Retinoid X Receptor) and bind to direct repeat sequences such 
as the Peroxisome Proliferator Activated Receptors (PPARs), Liver X Receptor (LXR), 
Farnesoid X Receptor (FXR), Retinoic Acid Receptor(RAR), and Vitamin D 
Receptor(VDR). Class III nuclear receptors also exist as homodimers but bind direct 
repeat sequences such as RXR,  and Class IV exist as monomers that bind half sites such 
as Steroidogenic Factor-1 Receptor (SF1R)[195]. 
Many of the Class II receptors are responsible for mediating lipid homeostasis including 
metabolism, storage, transport and elimination of lipids. They are activated by ligands 
such as fatty acids (PPARs), oxysterols (LXR), bile acids (FXR) and xenobiotics 
(SXR/PXR and CAR). Activation of these receptors often results in a feedforward 
positive regulation loop, since it occurs from low-affinity binding that happens at 
physiological concentrations influenced by dietary intake[196]. 
Currently 49 nuclear receptors have been identified in the human genome, and 31 of 
these are expressed in articular cartilage. Further, 23 of these are dysregulated in 
osteoarthritic cartilage[197]. However, only a few of these have been studied. 
29 
 
1.11.1 PPARs 
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor 
super family, with fatty acids and fatty acid-derived molecules functioning as naturally 
occurring ligands[198]. This is of particular interest to us due to emerging evidence 
linking obesity to osteoarthritis, in a subtype of primary OA known as metabolic OA[90]. 
Subchondral bone ischemia, compromised nutrient exchange, and oxidative stress have 
all been implicated as mechanisms for the initiation and progression of this subtype of 
OA. Furthermore, synthetic agonists and antagonists specific for PPARs have been 
developed for therapeutic reasons, and nuclear receptors have been indicated as a strong 
potential target for OA therapy[199]. PPARs heterodimerize with the Retinoid X 
Receptor (RXR) allowing for recruitment of co-activators or co-repressors to occur[200], 
and ligand binding to PPARs can either activate or repress target gene transcription, 
depending on the specific target gene and cellular context. PPARs also have a low level 
of basal or constitutive activity (Figure 1-4). Of the three subtypes [alpha, delta, gamma], 
PPARδ (also historically known as PPARβ) has the broadest expression pattern and 
functions in lipid and glucose metabolism, cell differentiation, proliferation, apoptosis 
and immune regulation. In skeletal muscle, it specifically activates pathways involved in 
remodeling with response to exercise[201]. While PPARα and PPARγ act as anti-
inflammatory factors, and could thereby confer protection from OA, PPARδ does not 
seem to share these anti-inflammatory attributes[202-205] Current studies on PPARγ 
indicate abnormal skeletal development in cartilage-specific knockout mice, as well as 
spontaneous osteoarthritis development in adult cartilage-specific knockout mice, 
indicating a role for PPAR proteins in controlling chondrocyte behavior[203, 206]. 
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Additionally, several studies on lipid metabolism illustrate how PPAR subtypes can have 
antagonistic and complementary action[207-210]. Thus a role of PPARδ in OA, and in 
particular in promotion of OA, is plausible, and supported by our own studies described 
below.  
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Figure 1-4 Nuclear receptor PPARδ 
In chondrocytes, endogenous fatty acids function as a ligand to activate PPARδ. In its 
inactive state, it remains bound to the nucleus with RXR. Upon ligand binding, it changes 
conformation, to its active form thereby enabling transcription of its gene targets. 
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1.12 Overall Objectives and Hypothesis 
Although OA affects all joint tissues, cartilage breakdown is a hallmark feature of OA 
and an irreversible process. PPARδ was initially identified as a possible target for OA 
therapy in several of our genome-wide gene expression studies[211-213]. Previously, we 
have shown that chondrocytes treated with the PPARδ agonist GW501516 respond with 
an increase in gene expression of several proteases involved in OA, including several 
ADAMTS and MMP genes[214]. Known target genes of PPARδ such as Lpl, Angpl4, 
and Pdk4 were also induced, confirming functionality of both PPARδ and GW501516 in 
chondrocytes.  
These data suggest that activation of PPARδ in chondrocytes promotes ECM degradation 
through increased expression of catabolic proteases. We have also demonstrated that 
PPARδ promotes fatty acid oxidation in chondrocytes[214], and there is potential that the 
dysregulation of lipid metabolism plays an important role in the initiation and progression 
of cartilage degeneration in OA[95]. Based on this data indicating that PPARδ promotes 
cartilage breakdown, the overarching hypothesis for my thesis is that inhibiting PPARδ 
will stop or delay cartilage breakdown in OA. 
1.12.1 Objective #1 
To characterize the role of PPARδ in Osteoarthritis, in-vivo, by generating cartilage-
specific Ppard knockout mice and examining them in a surgical model of OA. 
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1.12.1.1 Rationale #1 
Based on our in vitro data demonstrating catabolic effects of PPARδ activation, we asked 
whether inactivation of the Ppard gene would protect from cartilage degeneration in 
osteoarthritis. Mouse models are commonly used to study OA because they allow for 
genetic manipulations, and provide an efficient timeline using surgical models, enabling 
greater sample sizes[215]. Destabilization of the medial meniscus (DMM) is the most 
accepted surgical OA model in mice and use of genetically modified mice avoids 
potential complications from non-specific effects of pharmacological compounds[208, 
216, 217].  
1.12.1.2 Hypothesis #1 
Cartilage specific depletion of PPARδ will slow progression of post-traumatic OA. 
1.12.2 Objective #2 
 To determine the effects of pharmacological PPARδ inhibition in post-traumatic OA. 
1.12.2.1 Rationale #2 
The PPARδ agonist GW501516 induces protease expression and proteoglycan loss in-
vitro, and cartilage specific depletion of PPARδ in mice results in delayed progression of 
OA when compared to wild-type mice in a surgical model[214]. Yet, the effect of 
pharmacological inhibition of PPARδ in mediating response to injury (post-traumatic 
OA) has yet to be elucidated. While the genetic model has provided a strong foundation 
of information to characterize this gene’s role in the progression of OA, a 
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pharmacological approach is necessary to investigate whether the inhibition of PPARδ 
could be a feasible therapeutic target for OA in human patients.  
1.12.2.2 Hypothesis #2 
Pharmacological inhibition of PPARδ will protect against post-traumatic Osteoarthritis. 
1.12.3 Objective #3 
To elucidate novel target genes for PPARδ in chondrocytes. 
1.12.3.1 Rationale #3 
Our preliminary results suggest that PPARδ is important in the promotion of OA, but the 
underlying mechanisms remain unknown. Since PPARδ is a transcription factor, it most 
likely works by regulating the expression of target genes.To understand PPARδ’s mode 
of action, and identify additional targets for OA therapy, it is imperative that we first 
identify its target genes. 
1.12.3.2 Hypothesis #3 
PPARδ alters chondrocyte behavior by regulating gene expression. 
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Chapter 2  
2 PPARδ promotes the progression of post-traumatic 
osteoarthritis in a mouse model 
This chapter has been reproduced from Ratneswaran A, LeBlanc EA, Walser E, Welch I, 
Borradaile N, and Beier F. PPARδ promotes the progression of post-traumatic 
osteoarthritis in a mouse model. Arthritis Rheumatol. (2):454-64, 2015. 
2.1 Abstract 
Objective: Osteoarthritis (OA) is a serious and common disease of the entire joint, 
characterized by the degeneration of articular cartilage, subchondral bone changes, 
osteophyte formation and synovial hyperplasia. Currently, there are no pharmaceutical 
treatments to slow, stop or reverse disease progression, resulting in greatly reduced 
quality of life for OA patients and the need for joint replacement surgeries in many cases. 
The lack of available treatments for OA is partially due to our incomplete understanding 
of the molecular mechanisms promoting disease initiation and progression. Here we 
identify the nuclear receptor PPARδ as a promoter of cartilage degeneration in a mouse 
model of post-traumatic (e.g. injury-induced) OA. 
Methods: Mouse primary chondrocytes and knee explants were treated with 
pharmacological agonist of PPARδ (GW501516) to evaluate changes in gene expression 
(qPCR), histology (Safranin-O, immunohistochemistry), and matrix glycosaminoglycan 
breakdown (DMMB assay) consistent with OA, and potential recovery. In-vivo, PPARδ 
was specifically deleted in the cartilage of mice. Mutant and control mice aged 20 weeks 
were compared 8 weeks after a destabilization of medial meniscus (DMM) surgery. 
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Histopathological scoring (OARSI) and immunohistochemistry for known markers of OA 
were performed.  
Results: In vitro, PPARδ activation by the agonist GW501516 results in increased 
expression of several proteases implicated in cartilage matrix breakdown. GW501516 
also induces aggrecan degradation and release in a knee joint explant culture system. In-
vivo, cartilage specific Ppard knockout mice do not display any abnormalities of skeletal 
growth or development, but show marked protection in the DMM model of post-
traumatic OA (compared to control littermates). OARSI scoring and 
immunohistochemistry for cartilage matrix breakdown products confirm strong 
protection of the mutant mice from DMM-induced cartilage degeneration.  
Conclusion: These data demonstrate a catabolic role of endogenous PPARδ in post-
traumatic OA and suggest that pharmacological inhibition of PPARδ is a promising 
therapeutic strategy. 
Keywords: PPARδ, cartilage, osteoarthritis, knock-out mouse, destabilization of medial 
meniscus 
 
2.2 Introduction 
Osteoarthritis (OA) affects more than 150 million individuals worldwide and is 
predicted to rise in prevalence due to increasing life expectancies. OA severely influences 
the independence and quality of life of those afflicted; 14% of OA patients experience 
pain severe enough to significantly limit activities[1, 2]. Economically, OA accounts for 
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upwards of 190 billion dollar in North American direct and indirect health care costs 
annually, yet we have no current treatment modalities to prevent or delay its 
progression[3, 4].  
In recent years, the view of OA has shifted from what was fundamentally seen as a 
disease of “wear and tear” to the realization that OA is an active process marked by 
cartilage attrition, catalyzed by the induction of proteases targeting principal extracellular 
matrix components of cartilage. The responsible proteases, in particular 
metalloproteinases and ADAM-TS enzymes, target the major components of the cartilage 
extracellular matrix, type II collagen and aggrecan, respectively[5, 6]. Dysregulation of 
cartilage homeostasis results in chondrocyte proliferation, hypertrophy, and cell death, 
concurrent with articular cartilage fibrillation, erosion, subchondral bone thickening and a 
loss of joint congruity[7].  Ensuing functional consequences include joint pain, stiffness 
and loss of mobility[8].  However, previously published studies using human tissue 
obtained from end-stage OA have yielded little insight into the etiology of this disease[9-
11]. Thus it is essential to understand the molecular mechanisms underlying this 
condition throughout the disease process, in order to develop novel treatment approaches 
targeting core processes involved in cartilage remodeling and destruction. 
Another recent development has been the classification of metabolic Osteoarthritis, which 
encompasses the contributing roles of hypertension, dyslipidemia, hyperglycemia, and 
obesity in the development of OA[12].  Subchondral bone ischemia, compromised 
nutrient exchange, and oxidative stress have all been implicated as mechanisms for the 
initiation and progression of this subtype of OA.  In fact, a significant proportion of 
proteins related to lipid metabolism have been identified in proteomic analyses of 
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osteoarthritic cartilage and isolated chondrocytes[13].  Among these proteins are PPARs 
(Peroxisome Proliferator Activated Receptors), members of the nuclear receptor super 
family that are activated by lipid ligands.  Of the three subtypes (alpha, gamma, delta), 
PPARδ is most widely expressed and functions in lipid and glucose catabolism, cell 
proliferation, apoptosis and immune regulation.  In skeletal muscle, it specifically 
activates pathways involved in remodeling with response to exercise[14].  PPARδ has 
been detected in growth plate chondrocytes, and has been shown to be activated by the 
cytosolic Vitamin A metabolite retinoic acid[15, 16]. Vitamin A derivatives have been 
associated with the development of OA[17], suggesting that inhibition of PPARδ could 
constitute a novel approach for treatment of OA. In this study, we examined the effects of 
PPARδ activation in chondrocytes in vitro and the consequences of specifically deleting 
the encoding gene (Ppard) in cartilage of mice. Our data show that PPARδ activation 
promotes catabolic processes in cartilage and that its inhibition indeed protects from post-
traumatic OA in mice. 
2.3 Methods 
2.3.1 Primary Cell Culture and Isolation 
Chondrocytes were isolated from embryonic day 15.5 CD1 mice (Charles River 
Laboratories) as described[18] and placed in culture medium with 1% FBS at a density of 
1x105 per well. Cells were treated with the PPARδ agonist GW501516 at concentrations 
of 0.01 µM - 1 µM for 48 hours. Dimethyl sulfoxide (DMSO) treated cells served as 
vehicle control. 
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2.3.2 Palmitate-Oxidation Assay 
Primary chondrocytes were treated as above. Palmitate oxidation was assessed as 
previously described[19]. Radioactivity in the aqueous fraction of media and cell lysates 
was measured using a Beckman Coulter LS6500 Multipurpose Scintillation Counter.  
Total aqueous radioactivity, representing conversion of 3H-palmitate to 3H2O, was 
normalized to total protein.  
2.3.3 MTT assay 
Primary mouse chondrocytes plated at a density of 10,000 cells per well (96 well Falcon 
plate) were treated as above for 48 hours. Cell numbers were examined via MTT Assay 
as described[20], using a Cell Proliferation Kit (Roche Applied Science).  
2.3.4 RNA extraction and Real-Time Polymerase Chain Reaction  
Total RNA was isolated from cells using RNeasy kit (Quiagen). Real-Time Polymerase 
Chain Reaction (PCR) was performed using One-Step RT qPCR Master Mix kit and 
TaqMan Gene Expression Assays (Applied Biosystems) with 40 cycles on the ABI Prism 
7900 HT sequence detector (PrismElmer Life Sciences). Probes were purchased from 
Life Technologies for Mmp2 (Mm00439498_m1), Mmp3 (Mm00440295_m1), Mmp13 
(Mm00439491_m1), Adamts2 (Mm00805170_m1), Adamts5 (Mm00478620_m1), 
Adamts7 (Mm01239067_m1), Adamts12 (Mm00615603_m1), Acan (Mm00545794_m1), 
Col2a1 (Mm01309565_m1), Sox9 (Mm00448840_m1), Gapdh (Mm99999915_g1). Gene 
expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (Gapdh). 
Relative gene expression was calculated using the delta-delta Ct method[21], as 
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described[22, 23]. 
2.3.5 Explant Culture 
Knee joints from 10-week-old male CD1 wild-type mice (Charles River Laboratories) 
were isolated and placed in organ culture medium overnight. Knee joints were treated 
every 48 hours for 6 days with GW501516 (0.01 µM - 10 µM) or DMSO (10 µM) as 
vehicle control. Following organ culture, explants were fixed in 4% paraformaldehyde for 
24 hours. 
2.3.6 Dye Binding Assay 
Dimethylmethylene blue (DMMB) dye binding assay was performed on media collected 
from knee joint explant cultures. Knee joints were cultured with 1 µM of GW501516 or 
vehicle control DMSO (see above). After culture, epiphyses were isolated and cartilage 
was extracted and digested overnight according to[24]  DMMB assay was performed 
with chondroitin sulfate as a standard, and absorbance was measured on a Tecan Safire 
Fluorescence, Absorbance and Luminescence Reader  at a wavelength of 595nm with a 
reference wavelength of 655nm. Aggrecan released into the medium was normalized to 
total aggrecan present in each sample.[24].  
2.3.7 Tibia organ culture  
Tibias from E15.5 wild-type CD1 mice were treated every 48 hours for 6 days with 
DMSO (control, 1µM), GW501516 (0.01 µM - 10 µM), GSK3787 (1 µM), or 
combination treatment (1 µM GW501516 + 1 µM  GSK3787). Tibias were measured at 
the beginning and end of culture using an eyepiece in a Leica EC3 stereomicroscope. 
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Following organ culture, tibias were fixed in 95% paraformaldehyde for 24 hours, 
followed by paraffin embedding and sectioning[25, 26]. 
2.3.8 Animals and Surgery 
All animal experiments were approved by the Animal Use Subcommittee at The 
University of Western Ontario and conducted in accordance with the guidelines from the 
Canadian Council on Animal Care. Cartilage-specific Ppard KO mice were generated by 
breeding mice carrying the Cre-Recombinase gene under the control of the collagen II 
promoter[22, 23, 25, 26] to Ppardfl/fl mice (obtained from The Jackson Laboratory)[27]. 
Male mice were used for all of the subsequent experiments. Mice were harvested for 
analysis of skeletal development by staining whole mouse skeletons with Alcian 
Blue/Alizarian Red, as described[28, 29], or for preparation of paraffin sections. DMM or 
Sham surgery was performed by Dr. Ian Welch on 20 week old cartilage specific Ppard 
knockout mice and control littermates, as described[30, 31].  DMM- and sham-operated 
mice were harvested 8 weeks post-surgery for analysis. 
2.3.9 Histopathology of the Knee 
Knees were dissected, fixed in 4% Paraformaldehyde, decalcified in 
Ethylenediaminetetraacetic_acid (EDTA) and embedded in paraffin. Frontal sections 
were cut at the Molecular Pathology Facility[28] and stained with Safranin-O/Fast Green 
as previously described[32]. Serial sections were graded by three blinded observers 
according to the OARSI histopathological scale[33], on the four quadrants of the knee. 
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2.3.10 Immunohistochemistry (IHC) 
IHC was performed on frontal sections of paraffin embedded knees, slides with no 
primary antibody added were used as controls. Collagen 2 goat anti-human antibody was 
purchased from Santa Cruz Biotechnology (sc-774). Rabbit anti-human aggrecan (peptide 
CGGVDIPEN ovalbumin conjugate MMP cleavage site), Rabbit anti-human aggrecan 
(peptide CGGNITEGE ovalbumin conjugate ADAMTS 4/5 cleavage site) and Rabbit 
anti-cleaved collagen II (CGP-Hyp-GPQG ovalbumin conjugate human collagenase C1, 
2C) were used as primary antibodies[34-36]. 
2.4 Results 
2.4.1 PPARδ induces the expression of enzymes involved in 
proteoglycan breakdown 
GW501516 is a very specific, synthetic agonist of PPARδ[37]. Since PPARδ is an 
important regulatory gene in lipid metabolism in a number of tissues[38], and 
dysregulation of lipid metabolism has been implicated in OA, we first examined whether 
chondrocytes can respond to GW501516 by changes in lipid metabolism. To examine the 
extent of fatty-acid oxidation in primary mouse chondrocytes in response to GW501516 
treatment, a palmitate-oxidation assay was performed. A significant increase in fatty acid 
oxidation was observed upon GW501516 treatment, independent of agonist concentration 
(Figure 1A). This effect implies that chondrocytes express functional PPARδ and that 
oxidative lipid metabolism was fully induced at even the lowest concentration of drug 
treatment. MTT assays demonstrated that PPARδ activation did not alter cell number and 
therefore was not toxic to chondrocytes, even at the highest concentration (Fig. 2-1B). 
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In order to determine the effects GW501516 on gene expression in chondrocytes, 
quantitative RT-PCR (qPCR) was performed on RNA isolated from primary mouse 
cartilage cells treated with vehicle or various concentrations of GW501516. We first 
examined the effects of GW501516 on markers of extracellular matrix (ECM) synthesis 
and breakdown. PPARδ activation significantly increased the expression of genes 
encoding Matrix Metalloproteinases 2 and 3 (Mmp2, Mmp3) as well as A Disintegrin and 
Metalloproteinase with Thrombospondin Motifs 2, 5, 7, and 12 (Adamts2, 5, 7, 12) 
(Figure 2-1C-F and Suppl. Fig. 1A,B). This indicates that PPARδ induces expression of 
enzymes with the ability to cleave both the collagen and aggrecan components of the 
ECM. In contrast, no significant changes were observed for transcript levels of Mmp13, 
aggrecan and collagen II (Suppl. Fig. 1 C-E). Interestingly, the expression of Sox9, the 
key transcriptional regulator of collagen II and aggrecan genes, was slightly but 
significantly decreased with increasing concentrations of agonist (Suppl. Fig. 1F).  
We therefore investigated ECM turnover ex vivo using cultured knee explants.  Cultures 
were treated with GW501516 at 0.01, 0.1, 1, and 10 µM concentrations and stained with 
Safranin-O/Fast-Green. Loss of ECM glycosaminoglycans was observed with increasing 
concentrations of agonist treatment, consistent with aggrecanase activity (Figure 2-2A). 
Immunohistochemistry staining with neo-epitope antibodies confirmed degradation of 
aggrecan in the ECM (Fig. 2-2B) with 1µM agonist treatment compared to DMSO 
controls. Dimethylmethylene blue (DMMB) dye binding assays were also performed on 
knee explants cultured with GW501516 (1µM) or vehicle control (DMSO). Sulfated 
glycosaminoglycan released into the media was significantly greater for treated compared 
to untreated controls (Fig 2-2C).  In contrast, staining with antibodies for collagen II or 
62 
 
collagen II breakdown products showed no effect of PPARδ activation (Suppl. Fig. 2A,B, 
7). In agreement with the absence of detectable collagen II degradation, Picrosirius red 
staining for fibrillar collagen did not show major differences between treatments (Fig. 2-
2D). This is not unexpected as aggrecan loss precedes collagen loss during OA[39, 40]. 
Furthermore, the mechanical stimulation required for the breakdown of fibrillar collagen 
was not present in our culture system[41]. 
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Figure 2-1 PPARδ activation affects metabolism and gene expression in 
chondrocytes 
Primary mouse chondrocytes were incubated with DMSO or various doses of the 
PPARδ agonist GW501516 for 48 hours. A) PPARδ agonist treatment increased 
fatty acid oxidation in culture. Significant increases in β-oxidation were observed at 
all treatment concentrations. B) MTT assays demonstrate that GW501516 does not 
alter cell number, indicating greater concentrations are not toxic and observed 
results are not due to cell death. C) Relative Mmp2 gene expression is significantly 
increased at 0.1µm concentration of GW501516. D) Mmp3 gene expression is 
significantly upregulated at 0.1µM and 1µM concentrations of PPARδ agonist 
treatment. E) Adamts2 relative gene expression is increased at 0.1µM of GW501516 
treatment. F) PPARδ agonist treatment significantly elevates Adamts5 gene 
expression at 0.1µm and 1µM.  (N≥3, *p≤0.05, data represented are mean± SEM) 
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* 
Figure 2-2 Induction of proteoglycan degradation by  PPARδ agonism 
Adult mouse knee joints were incubated with DMSO (vehicle) or increasing 
concentrations of the PPARδ agonist GW501516 for 6 days (N = 3). A) Paraffin 
sections were stained with Safranin O (for cartilage glycosaminoglycans) or a neo-
epitope antibody for MMP13-cleaved aggrecan; B. Immunohistochemistry for 
cartilage explants used 1µM of GW501516 and DMSO vehicle control. C) A 
DMMB assay was performed to quantify sulfated glycosaminoglycan release into the 
media, (N=5). Picrosirius Red was also performed (fibrillar collagen; D). Safranin O 
staining (red) is reduced upon GW501516 treatment, while aggrecan neo-epitope 
staining (brown; indicated by red arrows) is increased. DMMB assay confirmed a 
significant difference between 1µM GW501516 treatment and DMSO controls. 
These results indicate increased glycosaminoglycan and proteoglycan breakdown in 
response to PPARδ activation. In contrast, Picrosirius Red staining (red) does not 
change dramatically. (N≥3) 
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2.4.2 Cartilage-specific PPARδ knockout mice display no 
developmental phenotype 
In light of these promising in vitro results, we initiated in vivo studies in order to 
determine whether PPARδ inhibition could be a valuable approach for OA therapy. We 
crossed Pppardfl/fl mice[27] with a strain expressing Cre recombinase under control of the 
collagen II promoter[28, 29, 42, 43]. We first assessed the developmental phenotype of 
cartilage-specific Ppard KO mice. Alcian Blue/Alizarin Red staining performed on 
skeletal preparations of postnatal day 10 (P10) and P21 control and Ppard knockout 
littermates (Figure 2-3A,D) demonstrated normal skeletal growth and morphology in 
mutant mice. Safranin-O staining was performed on paraffin sections on femurs from P10 
and P21 KO mice and wild-type littermates (without Cre) in order to assess growth plate 
development (Figure 2-3B,C,E,F). Measurement of the length of the proliferative zone, 
hypertrophic zone and total growth plate indicated normal phenotypes of mutant growth 
plates compared to wild-type mice. This was confirmed by normal morphology and tissue 
architecture of the mutant growth plates.  
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Figure 2-3 Cartilage-specific Ppard KO mice show no developmental phenotype 
A) Alcian Blue/ Alizarin Red Stains of P10 control and KO mice reveal no differences in 
skeletal size or morphology. B) Safranin-O staining of p10 proximal femoral growth 
plates reveal no differences in morphology in the resting, proliferative or hypertrophic 
zones. C) Measurements of these zones indicate similar skeletal development between 
genotypes at P10. D) Alcian Blue/ Alizarin Red staining of the mandible, arm, pelvic 
girdle and lower leg reveal no differences in growth or mineralization between 
genotypes at age P21. E) Safranin-O staining of P21 proximal femoral growth plates 
reveals no differences between WT and control mice. F) Measurements of absolute 
length indicate similar absolute length of resting, proliferative and hypertrophic zones at 
age P21. (N≥5) 
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In addition, to test the effects of GW501516 on skeletal growth, embryonic day 15.5 
(E15.5) tibias were isolated from wild-type CD1-mice and treated with the same 
concentrations of GW501516 as above for six days. There was no difference between 
treated and non-treated bones, as documented by measurement of tibia growth over the 
culture period and by Alcian Blue/Alizarin Red staining (Suppl. Fig. 3).  Finally, isolated 
wild-type E15.5 tibias were cultured in the same system with the PPARδ inhibitor 
GSK3787 or both the agonist and inhibitor together, in order to evaluate how PPARδ 
inhibition affects skeletal development. Similar to the in vivo results, there was no 
difference between treated, non-treated, or combination treated bones in mineralized bone 
length, absolute bone length (Suppl. Figure 3), or the length of growth plate zones and the 
total growth plate (Suppl. Figure 4). Thus, there is no obvious developmental phenotype 
in our mutant mice that would interfere with the analyses of OA pathology, and inhibiting 
PPARδ pharmacologically did not interfere with regular bone growth. 
2.4.3 PPARδ mutant mice display chondroprotection after surgical 
induction of Osteoarthritis 
At 20 weeks of age, cartilage-specific Ppard mutant mice and wild-type control 
littermates underwent a destabilization of medial meniscus (DMM) surgery [30] to induce 
OA, and sham surgery as control. Studies of baseline mice (without surgery) at this age 
show no difference in articular cartilage health and morphology between genotypes 
(Suppl. Fig. 5). 8 weeks post-surgery, mice were harvested and histopathological analyses 
were performed to determine the effects of Ppard inactivation on OA development and 
progression.  Eight serial frontal knee sections per mouse were assessed semi-
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quantitatively by three blinded scorers according to OARSI recommendations[33]. The 
OARSI method uses a combination of severity, breadth and depth of damaged surface to 
assign a score ranging from 0-6. The four quadrants of the knee were assessed both 
separately and cumulatively. Wild-type mice showed significant damage after DMM 
surgery, as expected, in particular on the medial side of the knee (in both femoral condyle 
and tibial plateau; Figure 2-4 A,B,C). Remarkably, mutant mice showed a much lower 
OARSI score after DMM surgery than their wild-type control littermates (Figure 2-4 
A,B,C). Damage in the KO DMM mice was restricted to focal glycosaminoglycan loss 
(Fig.2-4C), and OARSI scores were similar to those observed in sham-operated mice, as 
well as baseline control (no-surgery) mice. Cartilage degeneration was also assessed per 
animal (cumulative joint score) where results indicate a significant difference between 
WT DMM mice on one hand and KO DMM, sham-operated and control mice on the 
other hand (Figure 2-4D,E). As expected, lateral compartments showed very little 
damage and no significant differences between all groups (Suppl. Fig. 6). These results 
clearly demonstrate the chondroprotective role of Ppard inactivation in the DMM model 
and suggests that inhibition of PPARδ is a potential therapeutic strategy in 
OA.Immunohistochemistry was performed to elucidate downstream mechanisms of 
PPARδ inhibition (Fig. 2-5), with no-primary antibody controls (Suppl. Fig 7) Known 
markers of cartilage breakdown, e.g. MMP-cleaved aggrecan, ADAM-TS 4/5-cleaved 
Aggrecan, and  
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Figure 
Wild-type (WT) and littermate control cartilage-specific Ppard KO mice underwent 
DMM or sham surgery. 8 weeks after surgery, paraffin sections of joints were examined 
by Safranin O and OARSI scoring.  Cartilage Damage in the Medial Femoral Condyle 
(MFC) was assessed by three blinded observers according to the OARSI 
recommendations. A)The MFC of WT DMM mice had significantly more damage than 
those of KO DMM, or sham-operated mice. B) Cartilage Damage in the Medial Tibial 
Plateau (MTP) was significantly greater for WT DMM mice than any other group. The 
MTP was greatest affected quadrant of the knee. Ppard KO mice were protected from 
surgical induction of OA. C) Whole Joint OA was assessed from the cumulative scores 
of each quadrant. KO DMM and both sham-operated groups presented with minimal 
damage, whereas WT DMM mice developed the most damage. D) Representative 
Safranin O-stained sections from the medial compartment show cartilage degeneration 
in WT mice after DMM surgery, while KO mice only show focal loss of Safranin O 
staining. E) Representative Safranin O-stained sections from the total knee joint.  (N=5 
DMM/sham, *p≤0.05) 
 
Figure 2-4 Cartilage-specific Ppard KO mice are protected from DMM-induced OA 
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Figure 2-5 Cartilage-specific Ppard KO mice are protected from DMM-induced 
ECM degradation 
WT and cartilage-specific Ppard KO mice underwent DMM or sham surgery. 8 weeks 
after surgery, mice were sacrificed, and joints were examined by IHC staining of 
paraffin sections. IHC indicates a strong presence of aggrecan and collagen breakdown 
products after DMM surgery. WT DMM mice display more intense staining for ADAM-
TS4/5 and MMP13-cleaved aggrecan and collagen II in cartilage than all other groups. 
(N=5 per group) 
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MMP-cleaved collagen II were assessed using staining with neoepitope antibodies. WT 
DMM stained sections demonstrated intense staining for all three of these neoepitopes 
relative to sham-operated controls. In agreement with the OARSI scores, KO DMM mice 
showed much less neoepitope staining in cartilage. We can infer from these results that 
cartilage-specific Ppard KO mice are protected from ECM degradation in the DMM 
model of post-traumatic OA. 
2.4.4 Discussion 
Our study provides the first examination of the role of PPARδ in the pathogenesis of OA 
and provides insights to the underlying molecular mechanisms that regulate this disease.  
Through our in-vitro, ex-vivo and in-vivo models we have demonstrated the degenerative 
properties of PPARδ agonism in cartilage. 
Our in-vitro studies have established that PPARδ signaling in primary murine 
chondrocytes causes upregulation of genes capable of proteolytic activity on the cartilage 
ECM. Our ex-vivo experiments have validated these findings, with explants displaying 
glycosaminoglycan and aggrecan loss after treatment with GW501516. In addition, 
explants treated with the same agonist demonstrated significant glycosaminoglycan 
release into the media. This further illustrates the detrimental activity of PPARδ agonism 
on the cartilage ECM, especially glycosaminoglycans and proteoglycans. Alternatively, 
the PPARδ inverse agonist GSK3787 does not adversely affect skeletal growth or 
development in cultured embryonic tibiae. While these data suggest that PPARδ agonism 
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contributes to the pathological processes that drive OA, they also identify PPARδ 
inhibition as a potential therapeutic approach. 
Our in-vivo study demonstrates that inactivation of PPARδ specifically in cartilage 
confers significant protection from the progression of cartilage degeneration in the DMM 
model of post-traumatic OA.  Our study also demonstrates that inactivation of PPARδ 
results in decreased matrix breakdown products as the cartilage matrix remains relatively 
intact despite surgical induction of OA. Interestingly, our in vitro qPCR data did not 
show any induction of Mmp13 transcript levels by GW501516, but we observed strong 
reduction in MMP-generated cleavage products in our mutant mice after DMM surgery. 
One possible reason for this apparent discrepancy is that MMP13 activity is regulated at 
multiple levels, not only transcriptionally. For example, MMP3 (which is induced at the 
mRNA level by GW501516) activates MMP13 through proteolytic cleavage[44], 
possibly resulting in greater MMP13 activity despite constant Mmp13 mRNA levels. 
Additionally, increased collagen II neoepitope staining could result from MMP-2 
cleavage. MMP-2 is a collagenase, and was shown to be significantly increased after 
treatment with GW501516, indicating a potential alternative pathway for collagen II 
breakdown.  Our in-vitro data for qPCR shows a decrease in gene expression for certain 
catabolic markers (Mmp2, Adamts2, Adamts5, Adamts7, Adamts12) at 1 µM relative to 
the 0.1 µM treatment with GW501516. We cannot completely exclude that this is due to 
off-target effects of the drug at higher concentrations, but these effects could also reflect 
different sensitivity of different PPARδ target genes to the agonist. For example, only 
high doses of agonist suppress Sox9 mRNA levels; it is possible that these high doses are 
required for induction of specific target genes responsible for repressing the transcription 
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of Sox9 and possible some of the protease genes. Different levels of sensitivity to the 
agonist are also suggested by comparisons of the responses of metabolic target genes to 
the protease genes (discussed below).   
PPARδ is an orphan nuclear receptor that heterodimerizes with Retinoid X Receptor 
(RXR) inside the nucleus[45]. While all of the PPARs have lipids functioning as 
activating ligands, the same ligand can exert opposite effects on different nuclear 
receptors. For example, retinoic acid in the cytosol of keratinocytes has been shown to 
bind to both the Retinoic Acid Receptor and/or PPARδ, depending on which cytoplasmic 
transporter that it commits to. This determines whether the cell ultimately undergoes 
growth arrest or proliferation[16, 31]. Our recent studies on another PPAR subtype, 
PPARγ, indicate abnormal skeletal development in cartilage-specific knockout mice, as 
well as spontaneous osteoarthritis development in adult cartilage-specific knockout 
mice[46, 47]. Thus, PPARγ and δ potentially have opposing roles in OA development, 
with PPARγ acting in a protective and PPARδ in a degenerative manner. Several studies 
conducted in lipid metabolism illustrate how PPAR subtypes can have antagonistic and 
complementary actions[48-51], similar to our observations.  
We have also demonstrated that PPARδ promotes fatty acid oxidation in chondrocytes, 
and there is potential that the dysregulation of lipid metabolism plays an important role in 
the initiation and progression of cartilage degeneration in OA[52, 53]. In our study we 
noted that the concentration of PPARδ agonist needed to stimulate fatty acid oxidation is 
ten times lower than the concentration needed to promote catabolic enzyme activity. This 
suggests that PPAR protease genes are less sensitive to low levels of PPARδ activation 
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than lipid metabolism genes. As described earlier, our findings remain consistent with 
other studies,[48, 54] suggesting a significant amount of fatty acid oxidation upon 
PPARδ agonist treatment. In kidney cortical tubules and bovine articular endothelial 
cells, increased presence and activity of fatty acid oxidation enzymes is associated with 
greater oxidative phosphorylation and net reactive oxygen species (ROS) production[55, 
56]. Additionally, ROS have been implicated in the development of OA[57-59]. 
Consequently, this ability of PPARδ to induce ROS production could explain, at least in 
part, the opposite roles of PPARδ and PPARγ in osteoarthritis. It will be interesting to 
determine in the future whether altered lipid metabolism contributes to the function of 
PPARδ in OA, or whether direct induction of protease expression in response to robust 
PPARδ activation is required for cartilage destruction. The multi-factorial nature of OA 
and the different contributors to its development – such as mechanics, metabolism, age, 
and gender - give rise to a multitude of genes that may influence its progression and 
networks of molecules that determine its pathogenesis[9]. 
OA has extensive physiological, psychological and functional ramifications, and 
decreases mobility and increases the dependency of affected patients[60]. Our results 
indicating that cartilage-specific Ppard knockout mice are protected from OA may have 
tremendous potential for the treatment of OA through the identification of PPARδ as a 
new therapeutic target.  
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2.6 Supplementary Figures 
 
Figure 2-6, Supplementary Figure 1: PPARδ agonism induces catabolic gene 
expression 
  
A,B) Relative expression of ADAMTS-7 and ADAMTS-12 is significantly increased at 
0.1uM treatment with GW501516. C) Relative Expression of  MMP13 remains 
unchanged. D,E) Gene regulation of principal ECM components  Aggrecan, and 
Collagen II is not significantly altered after treatment. E) qPCR analyses demonstrates 
that Sox9 gene expression is slightly yet significantly decreased by GW501516 
treatment (N=3, *p<0.05) 
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Figure 2-7, Supplementary Figure 2: No changes in Collagen 2 content of joint 
explants treated with PPARδ agonist 
Immunohistochemistry (IHC) for Collagen 2 on 10 week knee organ culture explants 
treated for 6 days with PPARd agonist GW501516 indicate no change in Collagen 2 or 
Collagen 2 breakdown product staining. A) IHC reveals no staining difference between 
vehicle controls (DMSO) or agonist treated explants for type-2 Collagen. B) IHC staining 
reveals no difference between controls or treated Collagen-2 neoepitopes in the matrix of 
cultured knee explants. 
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Figure 2-8, Supplementary Figure 3: Bone length and mineralization remains 
constant after PPARδ agonist and inhibitor treatment 
E15.5 tibias isolated from wild-type CD1 mice were cultured for 6 days with 
GW501516, GSK3787 (PPARδ inhibitor), GW501516+GSK3787, or DMS0 at 1µM 
concentrations. Measurements were taken immediately after dissection and before 
fixation. A) Alcian blue (cartilage)/Alizarin Red (bone) staining of tibias revealed no 
morphological differences between treatments. B) There was no change in length of 
the mineralized section of bones between treatments. C) No change in absolute length 
of bones was observed after treatment. N=3 
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Figure 2-9, Supplementary Figure 4: E15.5 mouse tibia organ cultures reveal no 
effects of pharmacological PPARδ manipulation 
E15.5 mouse tibias were isolated and cultured with 1µM agonist (GW501516), inhibitor 
(GSK3787), both, or vehicle (DMSO).  A) Measurements of the proliferative, 
hypertrophic, and total growth plate of the proximal tibia indicate no difference in zone 
length between treatments. B) Safranin-O/Fast Green Staining of tibias demonstrate 
normal growth plate morphology. The resting-proliferative borders are indicated with 
green arrows, while the proliferative- hypertrophic borders are indicated with red arrows. 
(N≥3) 
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Figure 2-10, Supplementary Figure 5: Assessment of knee cartilage at baseline 
Representative Safranin-O images of medial, lateral and whole-joints from 20 week-old 
base-line naïve mice show healthy articular cartilage with regular proteoglycan staining. 
(N≥3) Cumulative OARSI scores from all four quadrants indicate no difference in 
cartilage health between WT and PPARd KO mice. 
 
 
81 
 
 
 
 
 
Figure 2-11, Supplementary Figure 6: OARSI scoring does not indicate differences 
in lateral compartments of the knee after DMM surgery 
A) Safranin-O stained joints reveal little proteoglycan loss or articular cartilage damage 
across genotypes and surgical conditions in the lateral femoral condyle and lateral tibial 
plateau 8 weeks post-surgery. B,C) Cumulative OARSI scores of the Lateral Femoral 
Condyle and the Lateral Tibial Plateau indicate minimal damage to the articular surfaces 
of the lateral knee. (N=5 DMM/sham) 
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Figure 2-12, Supplementary Figure 7: No-primary antibody controls for cartilage 
knee explants and surgical trial mice 
No primary controls for Immunohistochemical staining displays no staining for MMP 
cleaved aggrecan, collagen 2, MMP cleaved collagen 2 with hematoxylin counterstain in 
explant cultures (above). No primary antibody staining for MMP cleaved aggrecan, 
ADAM-TS 4/5 cleaved aggrecan, and MMP cleaved collagen 2 displays no staining with 
methyl green counterstain in mice after surgery (below). 
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Figure 2-13, Supplementary Figure 13: Gait Analysis on mice post DMM surgery 
reveals no changes between groups 
8 weeks post-DMM surgery, both PPARδ and WT control littermates underwent gait 
analysis on the Noldus CatWalk™. Measurements were calculated as an average of 5 
runs, and normalized relative to the ipsilateral limb. There were no differences between 
either group in A) Paw Intensity, B) Stride Length, or C) Swing Speed.  
 
 
A B 
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Chapter 3  
3 Effects of pharmacological administration of PPARδ 
inhibitors on post-traumatic osteoarthritis 
These data are currently unpublished but will contribute to an original first author 
research paper to be submitted for publication. 
Ratneswaran A, Pest MA, Hamilton C, Dupuis H, Pitelka V, Chesworth B, and Beier F. 
Effects of pharmacological administration of PPARδ inhibitors on post-traumatic 
osteoarthritis. To be submitted to Arthritis and Rheumatology, 2016. 
3.1 Abstract 
Objective: Currently there are no effective drugs to alter the course of disease 
progression in Osteoarthritis (OA). Post-traumatic osteoarthritis (PTOA) is a subtype of 
OA that is initiated by joint trauma. We have previously demonstrated that genetic 
ablation of the nuclear receptor PPARδ results in protection from cartilage damage after 
induction of PTOA in a murine model. We aim to characterize whether pharmacological 
inhibition of  PPARδ is a feasible treatment to stop or delay the progression of 
osteoarthritis.  
Methods: PTOA was induced in male rats via anterior cruciate ligament transection 
(ACLT) with partial medial meniscectomy (PMMx) surgery, with SHAM surgery as 
control. PPARδ inhibitors (GSK0660, GSK3787) or vehicle control (DMSO) were 
administered daily for four weeks (6 days on, 1 day off) via subcutaneous injection at a 
dose of 1mg/kg. Behavioural outcomes were assessed through Open Field Testing and 
91 
 
Incapacitance testing. Structural progression of OA was evaluated using Toluidine Blue 
staining of paraffin sections with histopathological scoring, and polarized picrosirius red. 
Results: Rats undergoing ACLT/PMMx surgery exhibited behavioral changes (less 
movement and vertical activity) that were blocked by either PPARδ inhibitor. However, 
PPARδ inhibition did not significantly protect from progression of cartilage and 
subchondral bone damage. 
Conclusions: PPARδ inhibition positively affects functional outcomes after PTOA 
induction in rats, but our current data do not indicate efficacy to alter disease progression. 
3.2 Introduction 
Osteoarthritis (OA) is a musculoskeletal disorder that culminates with joint failure. It may 
affect one or more joints, and can stem from systemic or local factors that initiate a 
cascade of inflammatory and degradative events in one or more joint tissues, leading to 
impaired function and joint pain[1-3]. While primary age-associated OA predominantly 
affects individuals over the age of 60, post-traumatic OA (PTOA) affects younger 
individuals - usually starting under the age of 40[4]. Primary OA is characterized by the 
gradual deterioration of articular cartilage, synovitis and remodeling and 
hypomineralization of subchondral bone[5, 6]. PTOA shares many of these 
characteristics in its later stages but its initial and acute stages are markedly different.  
PTOA develops after joint trauma, particularly mechanical overload from ligament or 
meniscus injuries and results in 900,000 new cases annually in the U.S[6]. Initial impact 
from injury can cause destruction to the collagen 2 framework of the cartilage ECM, as 
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well as glycosaminoglycan loss and chondrocyte death[7, 8]. Cartilage can shear from the 
subchondral bone plate, and fractures of the articular cartilage and underlying bone can 
occur. Bone marrow edema, and hemarthrosis are also common features of PTOA[9, 10].  
In the months after the injury, there is sustained systemic inflammation through increased 
expression of inflammatory markers such as IL-6 and TNF-α in synoviocytes, and IL-1 in 
both synoviocytes and chondrocytes[11]. These inflammatory mediators can act on the 
synovium and cartilage to induce expression of matrix degrading enzymes such as the 
matrix metalloproteinases (MMPs)[12]. As a consequence of hemarthrosis and 
inflammatory cell invasion, the synovial fluid has decreased concentrations of both 
hyaluronic acid and lubricin[13, 14].  Eventually, the inflammatory response subsides but 
20-50% of any joint trauma still leads to the progression of OA[15]. PTOA can develop 
even after reconstructive surgery to repair ligaments, joint congruity and mechanics. 
Unfortunately, the age demographic of PTOA combined with the limited lifespan of 
implants renders joint replacement surgery a poor option[4, 16]. Currently, there are no 
treatments to stop the structural progression of OA and no effective chronic pain 
medications to ameliorate the burden of disability for patients experiencing this 
condition[17].  
Nuclear receptors have been suggested as attractive pharmacological targets due to their 
ability to bind ligands and regulate transcriptional activity[18]. Our previous studies have 
shown the that the nuclear receptor PPARδ promotes induction of proteases and 
destruction of articular cartilage in-vitro. We have also demonstrated that inhibition of 
PPARδ, through cartilage specific inactivation of the Ppard gene protects against 
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cartilage degeneration after surgical induction of OA through a destabilization of medial 
meniscus (DMM surgery)[19]. However, to determine whether inactivation of PPARδ 
could be a feasible treatment option for humans with PTOA, we needed to characterize if 
pharmacological inactivation of PPARδ protects against the progression of PTOA.  
In the present study, we examined the effects of pharmacological PPARδ inhibition on 
OA progression, after surgical induction of OA through anterior cruciate ligament 
transection (ACLT) and partial medial meniscectomy (PMMx). Our data showed that 
PPARδ inhibition results in improved functional outcomes 4 weeks after surgery, yet 
unaltered structural pathology. 
3.3 Methods 
3.3.1 Animals and Surgery 
All animal experiments were approved by the Animal Use Subcommittee at The 
University of Western Ontario and were conducted in accordance with the guidelines 
from the Canadian Council on Animal Care. Rats were group housed (2 rats per cage) 
preceding surgery, on a standard 12h light/dark cycle with free access to standard rat 
chow and water. Rats were separated to single housing post-surgery.  
Anterior cruciate ligament transection (ACLT) with partial medial meniscectomy 
(PMMx)  surgery or SHAM surgery was performed on the right knees of male rats 
weighing 300-350g (Charles River Laboratories, Quebec, Canada) at baseline, as 
described [20, 21]. Isofluorane (5% induction, 2% maintenance) was used as surgical 
anesthetic. Saline (9g/L NaCl, 5 mL total) was administered postoperatively for 
hydration. Buprenorphine (0.1 mg/kg x2) was administered intramuscularly as a post-
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operative analgesic, and ampicillin (10mg/kg x 2) was administered subcutaneously as a 
prophylactic antibiotic. Rats were randomly allocated to one of four groups, 
ACLTx/PMMx with vehicle control (DMSO), PPARδ inhibitor GSK3787, PPARδ 
inhibitor GSK0660, or SHAM operation (with DMSO). Rats were injected 
subcutaneously with one of the above specified treatments for 6 days a week for 4 weeks.  
Weight was measured weekly. Rats were euthanized at 4 weeks post surgery for 
preparation of paraffin sections, blood glucose and liver weight measurements, and 
subsequent histological analysis.  
3.3.2 Behavioural Testing 
Exploratory behaviour in rats was assessed by measuring spontaneous locomotor activity. 
Rats were placed in an Open Field Tester (Omnitech Electronics Inc., Columbus Ohio) 
for 30 minutes, 1 day per week in the dark. Rest, movement, ambulation and vertical 
activity time and incidence were measured as a proxy for OA pain, as described [22].   
Incapacitance testing was conducted to measure load distribution per limb. Rats were 
placed on an incapacitance tester (Linton Instruments, Norfolk, UK) and ipsilateral: 
contralateral limb load was calculated to measure change in load distribution or 
compensation after surgery as per [22]. 
3.3.3 Histopathology and Scoring 
Right knees were dissected, fixed in 4% paraformaldehyde, decalcified in Formical-4TM 
(StatLab, Baltimore, MD), bisected along their coronal plane, embedded in paraffin and 
sectioned frontally. Serial sections of 6µM width were stained with Toluidine Blue for 
glycosaminoglycan content and subsequent histopathological scoring or with Picrosirius 
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Red (0.1% Sirius red in picric acid) for staining of collagen fibril content and 
organization[23]. Polarized light microscopy was used to evaluate size and organization 
of collagen fibrils, and light intensity and tissue angle were kept identical between 
samples as per [23]. 
Toluidine Blue stained sections were evaluated by 2 blinded observers, and cartilage 
degeneration and subchondral bone damage in four quadrants of the knee were graded 
using the Osteoarthritis Research Society International (OARSI) histopathologic 
scale[24]. 
3.3.4 Statistical Analysis 
All statistics were performed in GraphPad Prism v.6.2. Blood glucose, liver weight and 
incapacitance-testing were analyzed by one-way analysis of variance (ANOVA) followed 
by Bonferroni’s multiple comparisons test. Weight change over time was analyzed using 
a one-way ANOVA with repeated measures. Open Field Testing for spontaneous 
locomotor behaviour was analyzed using a two-way repeated measures ANOVA with 
Bonferroni post-hoc test. OARSI histopathological scoring was analyzed using a Kruskal-
Wallis test followed by Dunn’s post-hoc. 
3.4 Results 
3.4.1 Rats treated with PPARδ inhibitors do not demonstrate 
systemic abnormalities  
PPARδ is a regulator of metabolism in many tissues, and to evaluate whether systemic 
delivery could cause physiological and anthropometric changes we measured weight 
change, blood glucose and liver weight. There was no difference in body weight over the  
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time-course of four weeks post-surgery between rats that received DMSO, GSK3787, 
GSK0660 or the SHAM operation (Fig 3-1). Similarly, there were no differences in blood 
glucose or liver weight between groups at 4 weeks post-surgery. 
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Figure 3-1 Anthropometric and Physiological Characteristics after PPARδ 
inhibition and surgical induction of OA 
Over the course of 4 weeks post-ACLT/PMMx or SHAM surgery, rats do not 
demonstrate differences in body weight (g) regardless of vehicle control (DMSO), 
GSK3787, or GSK0660 treatment (A). Similarly, there were no significant 
differences in blood glucose (mmol/L) or liver weight (g) four weeks post-surgery 
between any of the treatment groups (B, C). N=5 per group, data shown are 
mean±SEM. 
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3.4.2 Rats receiving PPARδ inhibitors are protected from OA-
induced behavioral changes 
To evaluate changes in behavior that were indicative of pain, rats were examined through 
Open Field Testing to measure changes in spontaneous locomotor activity. Throughout 
the course of 4 weeks, as rats developed more severe structural pathology, rats who 
underwent ACLT/PMMx and were administered DMSO significantly modified their 
behavior by resting more (Fig 3.2), and performing less vertical activity (Fig 3-2). This 
increase in pain behavior was not experienced by rats who received either PPARδ 
inhibitor, or rats who underwent the SHAM operation, suggesting that they were not 
experiencing the same level of pain.  
3.4.3 Rats receiving PPARδ inhibitors do not alter load distribution 
in hind-limbs 
In order to investigate whether there were changes in load distribution between the 
surgically operated limb and contralateral limb, Incapacitance testing was employed. As 
OA progresses, behaviour is modified to place less weight on the joint that is affected; 
accordingly 4 weeks post-surgery rats in the ACLT/PMMx group treated with DMSO 
compensated, increasing the weight on the contralateral limb and thus decreasing the 
ipsilateral:contralateral ratio (Fig 3-3). 
3.4.4 Histopathological Scoring does not indicate significant 
differences in disease progression with PPARδ inhibition 
At 4 weeks post-surgery, rats were euthanized and their joints were harvested for 
histopathologic analyses to determine the effect of PPARδ inhibition on the progression 
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of OA. Eight serial frontal sections per rat were assessed semi-quantitatively by 2 blinded 
observers using the OARSI recommendations[24].  Cartilage degeneration was scored by  
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Figure 3-2 PPARδ  inhibition prevents rats from OA pain like behavioural 
modification post-surgery 
Open Field Testing over the course of four weeks demonstrates changes in 
spontaneous locomotor activity. Rats receiving DMSO daily for four weeks post-
ACLT/PMMx (green bar) demonstrate pain invoked behavior modification such 
as increased rest time (A) and decreased vertical activity (B). These changes were 
not seen in SHAM operated rats (purple bars) or rats undergoing post-
ACLT/PMMx surgery with either PPARδ inhibitor (orange, red bars).  N=5 per 
group, data shown are mean±SEM, p≤0.05. 
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Figure 3-3 PTOA causes load redistribution in hind-limbs 
4 weeks post ACLT/PMMx surgery, rats underwent Incapacitance testing to determine 
load placed on each of the hind limbs. Rats who underwent surgical induction of OA, and 
were administered vehicle control DMSO significantly favoured their un-operated limb, 
demonstrating decreased ipsilateral: contralateral weight bearing. N=5 per group, data 
shown are mean±SEM, p≤0.05.  
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Figure 3-4 Rats receiving PPARδ  inhibitors still experience cartilage degeneration 
and subchondral bone changes 
Toluidine Blue staining on serial frontal sections indicates severe cartilage erosion in the 
medial femoral condyle and medial tibial plateau of rats treated with DMSO after surgical 
induction of OA via ACLT/PMMx. Articular cartilage collapse into subchondral bone 
and chondrogenesis is apparent. GSK0660 treated rats have observed cartilage shearing 
and focal cartilage defects as well as fractures of the tidemark and marrow changes. 
Similarly, GSK3787 treated rats experience cartilage shearing, proteoglycan loss, 
subchondral bone thickening and chondrogenesis in underlying bone. SHAM operated 
rats present with healthy cartilage, subchondral bone and menisci. 
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Figure 3-5 Semi-quantitative assessment of knee joint histopathology after surgical 
induction of PTOA 
Structural progression of OA was semi-quantitatively assessed via OARSI scoring for 
cartilage degeneration, and subchondral bone damage. DMSO (vehicle control) treated 
rats had significantly more cartilage, and subchondral bone damage in either quadrant of 
the medial side versus SHAM operated animals. N=5 per group, data shown are 
mean±SEM, p≤0.05. 
 
 
 
103 
 
 
subdividing the quadrant into thirds (outer, mid, inner) and scoring each third from 0-5, 
with 0 being no degeneration and 5 indicating severe degeneration with more than 75% 
of cartilage lost. Each of the thirds is summed, and the aggregate score is out of 15. 
Subchondral bone and calcified cartilage was also evaluated with a score of 0-5; 0 
indicating no pathology and 5 indicating severe pathology with articular cartilage 
collapse into subchondral bone and the formation of bone cysts. Rats that underwent the 
SHAM operation had healthy cartilage and subchondral bone. Rats that underwent 
ACLT/PMMx followed by treatment with vehicle control DMSO, GSK3787 or GSK0660 
experienced varying degrees of focal fibrillation, glycosaminoglycan loss, and 
subchondral bone remodeling (Fig. 3-4) This damage was most severe in the 
ACLT/PMMx DMSO group which was significantly different compared to the SHAM 
operated group in terms of cartilage degeneration and subchondral bone damage in the 
medial femoral condyle, and medial tibial plateau (Fig 3-5). This damage was not 
significant between either PPARδ inhibitor treated group and the surgically induced OA 
DMSO treated rats, or the SHAM group. These data suggest that the effects of PPARδ 
inhibition might be somewhat protective but not statistically significant within the 
experimental parameters. 
3.4.5 Picrosirius red staining indicates bone remodeling in vehicle 
control rats but not in PPARδ inhibitor treated rats 
Picrosirius red staining was performed on frontal sections from rats that underwent 
surgical induction of OA and SHAM rats. Stains were imaged under polarized light, 
where healthy articular cartilage showed mixed tones of orange with green and yellow 
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birefringence. Interestingly, the articular cartilage from the rats after surgery had largely 
orange birefringence, indicating a change in fibril organization. The subchondral bone 
had clear trabeculae. In contrast, the ALCT/PMMx vehicle controls presented with strong 
yellow and green fibers oriented in the same plane, indicating remodeling activities (Fig. 
3-6).  
3.5 Discussion 
OA is a common, debilitating problem affecting individual quality of life and places an 
enormous economic burden on health and social services[25]. PTOA comprises 12% of 
OA cases and follows a distinct pathogenesis with immediate and acute phases of the 
disease largely contributing to irreversible joint damage[4, 6]. Arguably, early 
interventions have tremendous potential to limit or delay damage. 
Our study examines whether inhibition of the nuclear receptor PPARδ can delay the onset 
or progression of OA after surgical induction of PTOA through ACLT/PMMx. We 
discovered that systemic treatment of rats with PPARδ inhibitors demonstrate a supressed 
behavioral response, and maintenance of normal function over the course of four weeks. 
In a previous paper published by our group, we demonstrate functional deficits in vertical 
activity and rest time after ACLT/PMMx[22]. Our study replicated this finding; vehicle 
control rats after surgery had decreased vertical activity and increased rest time 
(decreased movement time).  
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Figure 3-6 Examination of Collagen fibre structure and organization 
Picrosirius red staining under polarized light reveals changes in subchondral bone 
organization and structure. Strong yellow and green birefringent band in ACLT/PMMx 
DMSO group indicates change in collagen fibril organization and bone structure. (N=5 
per group).  
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We also showed inhibitor treated rats and SHAM rats do not, further cementing improved 
functional outcomes with PPARδ inhibition. Together these data suggest that PPARδ 
inhibition protects from pain caused by surgical induction of PTOA. 
Joint pain in OA has a complex pathophysiology; chronic pain can result in mechanical 
allodynia where even innocuous stimuli can elicit a pain response[26]. It can also result in 
hyperalgesia, where stimuli distant to the joint can cause pain[27]. We first considered 
whether the pain could be correlated with structural protection from the progression of 
OA. Indeed, the severity of cartilage degeneration and subchondral bone damage 
appeared less advanced in the PPARδ inhibitor treated animals, but it did also not did not 
confer significant protection according to semi-quantitative histopathological assessment. 
Our group has previously demonstrated that PPARδ agonism results in the induction of 
matrix degrading enzymes, significant upregulation of fatty-acid oxidation and inhibitors 
of anti-oxidants in chondrocytes [Ratneswaran et al, submitted]. These data indicate that 
inhibition of PPARδ could protect cartilage and possibly bone by reducing aberrant beta-
oxidation and oxidative stress. It is therefore likely that some of the pain relief that we 
observe is correlated with attenuated structural pathology. 
However, it is important to note that structural progression is not always associated with 
joint pain in OA. A number of individuals with established radiographic disease are 
asymptomatic for pain[28]. It is also probable that PPARδ acts directly on the nervous 
system to influence pain behaviour. PPARδ is the most highly expressed PPAR protein in 
the central nervous system,  and is expressed throughout the brain, in oligodendrocytes 
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and neurons[29]. In particular, it is present in the thalamus, indicating that it may play a 
role modulating response to pain[30]. Further, COX-2 inhibitors have been shown to 
suppress PPARδ expression and have been used clinically (Rofecoxib) as NSAIDs in 
osteoarthritis to ameliorate inflammation associated pain, indicating a possible 
mechanism for the changes we see[30, 31]. 
PPARδ is broadly expressed in the body, and has roles in glucose and lipid metabolism, 
cell proliferation, apoptosis, and immune regulation[32]. Although systemic delivery of 
PPARδ inhibitors did not result in deleterious physiological changes, it was only over a 
time course of four weeks. If PPARδ inhibitors are a feasible therapeutic target for OA, 
they need to be locally delivered to the joint, and longer time courses must be evaluated. 
Additionally, we will need to evaluate the quantity of drug that reaches the cartilage. We 
will also need to to increase the N of our experiments to examine whether the observed 
trend towards structural protection by PPARδ inhibitors reaches statistical significance.  
It would also be informative to evaluate the role of PPARδ inhibition in early OA, and in 
other subtypes of OA such as metabolic OA and age-associated OA to investigate 
whether the protection conferred would be similar. Our study has elucidated the 
feasibility of PPARδ inhibition in post-traumatic OA. We have shown that PPARδ 
inhibition results in decreased pain-associated behaviour, and this may be modulated 
through delayed structural progression. The molecular mechanisms underlying OA 
remain poorly understood, and in order to deliver an effective treatment for PTOA we 
must continue to explore these mechanisms, concurrent with methods of local drug 
delivery. 
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Chapter 4  
4 Nuclear receptors regulate lipid metabolism in 
chondrocytes 
These data have been submitted to Arthritis and Rheumatology and are awaiting review. 
Ratneswaran A, Sun MMG, Dupuis H, Sawyez C, Borradaile N. and Beier F. Nuclear 
receptors regulate lipid metabolism in chondrocytes. Arthritis Rheumatol. Submitted.  
4.1 Abstract 
Objective: Failure of joint homeostasis can result in osteoarthritis (OA). Metabolic OA is 
characterized by dysregulation of lipid and cholesterol metabolism which can 
detrimentally affect cartilage. Currently, there are no available treatments to alter disease 
progression in OA, but targeting early changes in cellular behaviour has great potential. 
Recent data show that nuclear receptors contribute to the pathogenesis of OA and could 
be viable therapeutic targets, but their molecular mode of action in cartilage is 
incompletely understood. The purpose of the present study was to examine global 
changes in gene expression after treatment with agonists of four nuclear receptors 
implicated in OA (LXR, PPARδ, PPARγ and their heterodimeric partner RXR). 
Methods: Immature murine articular chondrocytes were treated with pharmacological 
agonists for LXR, PPARδ, PPARγ or RXR and underwent microarray analysis, qPCR 
and cell lipid assays to evaluate changes in gene expression, expression, and lipid profile. 
Immunohistochemical analysis was conducted to compare presence of one identified 
differentially expressed target (Txnip) in WT mice and cartilage-specific PPARδ 
knockout mice subjected to surgical destabilization of the medial meniscus (DMM). 
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Results: Nuclear Receptor agonists increased expression of several genes regulating lipid 
metabolism, but each agonist induced a differential profile of responses. LXR activation 
downregulated gene expression of proteases involved in OA, whereas RXR agonism 
decreased gene expression of ECM components, and increased gene expression of 
Mmp13. Functional assays indicate increases in cell triglyceride accumulation after 
PPARγ, LXR and RXR agonism but a decrease after PPARδ agonism. PPARδ and RXR 
both downregulate the antioxidant GSTA4, and PPARδ upregulates Txnip. WT, but not 
PPARδ-deficient mice display increased staining for Txnip after surgical induction of 
OA. 
Conclusions: These data demonstrate that nuclear receptor activation in chondrocytes 
primarily affects lipid metabolism. In the case of PPARδ this change might lead to 
increased oxidative stress, possibly contributing to OA-associated changes described 
earlier. 
Keywords: Cartilage, chondrocyte, joint, lipid metabolism, osteoarthritis, oxidative stress 
4.2 Introduction 
Joint homeostasis is an integral process determining the functional load bearing 
capabilities of the joint that are essential to ensuring mobility and preventing morbidity. 
Dysregulation of this process can result in osteoarthritis (OA), a collective of 
heterogeneous pathologies culminating in joint failure. OA presents with similar 
pathological end points but mechanisms of initiation and progression vary among 
subtypes of this disease, which is one of the leading causes of disability worldwide[1, 2].  
Its varied presentation influences whether it is symptomatic or not, and even whether it 
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can be diagnosed radiographically. Multiple tissues such as the articular cartilage, 
subchondral bone, synovium, meniscus, and fat pads are involved in this condition, and 
initiation of this disease can stem from mechanical, metabolic, or age-associated factors 
although none of these are mutually exclusive.  
The main function of cartilage is to act as a shock absorber, mediating load bearing 
through the influx and efflux of water attracted to the proteoglycan aggregates forming 
the main protein component of the extracellular matrix, and tensile strength through 
collagen fibril organization[3]. Although cartilage cells contribute to a small percentage 
of the volume of the entire joint, they are sensitive to changes that occur to changes in 
gene expression in models of OA, thus underscoring their importance in joint 
homeostasis. 
Metabolic OA has been classified as a distinct subtype of OA associated with disorders 
such as dyslipidemia, hypertension and obesity. Imbalances in systemic lipid and 
cholesterol metabolism, nutrient exchange, accumulation of advanced glycation end 
products, and increases in adipokines contribute to this condition. Changes in lipid 
metabolism, in particular, may directly affect joint homeostasis through ectopic lipid 
deposition in chondrocytes[4-7]. In fact, both chondrocyte specific cholesterol 
accumulation and high fat diet have caused increased disease severity in murine 
models[8-10]. Collectively these data suggest direct regulation of cartilage homeostasis 
by lipid metabolism.  
Nuclear Receptors are a class of proteins that are activated by small molecule ligands and 
can up or downregulate the expression of target genes through the recruitment of co-
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factors or co-repressors. They have been reported as attractive potential targets for 
pharmacological therapy because of their ability to bind synthetic or natural ligands that 
regulate transcriptional activity[11].  As such, synthetic agonists for nuclear receptors 
have been developed targeting metabolic conditions such as dyslipidemia, 
atherosclerosis, and diabetes [12, 13]. PPARs (peroxisome proliferated activated 
receptors) are typically involved in the control of lipid metabolism and activated by the 
binding of endogenous fatty acids, whereas LXR (liver X receptor) is principally 
involved in cholesterol metabolism. Recently, we have shown that cartilage-specific 
ablation of the gene encoding the nuclear receptor PPARδ has a protective effect on 
cartilage after surgical induction of OA, demonstrating that PPARδ promotes post-
traumatic OA. Conversely PPARγ and LXR are protective and necessary for normal joint 
function and skeletal development [14-17]. Interestingly, all three of these receptors act 
in heterodimers with the common partner RXR, positioning RXR at the centre of a 
complex network of nuclear receptors. All of these proteins are expressed in cartilage[16, 
18, 19]. 
In this study we have used microarray analysis paired with functional validation to 
identify gene targets of LXR, PPARγ, PPARδ and RXR in articular chondrocytes, in 
order to elucidate their potential role in OA pathogenesis. There is strong evidence 
implicating the involvement of nuclear receptors in the progression or prevention of OA, 
and here we provide insight as to how they may be involved in altering the gene 
expression profile and phenotype of mature, healthy chondrocyte cultures. We are also 
the first, to our knowledge, to quantify changes in neutral lipid and free cholesterol mass 
in chondrocytes in vitro. This information is essential in uncovering the early changes 
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that occur in chondrocytes before irreversible phenotypic changes within the joint, and is 
vital since we currently have no effective biomarkers or treatment to alter the course of 
OA progression. Our data demonstrate that changes in gene regulation after nuclear 
receptor agonist treatment primarily affect lipid metabolism, suggesting a close link 
between lipid metabolism within chondrocytes and the progression of OA.  
4.3 Methods 
4.3.1 Primary Cell Culture and Isolation 
Immature murine articular chondrocytes (IMACs) were isolated from the femoral head, 
femoral condyle, and tibial condyles of 5-6 day old CD1 mice (Charles River 
Laboratories). The tissue was then subjected to one hour (3 mg/ml) followed by 24 hour 
(0.5 mg/ml) incubations in Collagenase D diluted in Dulbecco’s Modified Eagles 
Medium supplemented with 2 mM l-glutamine, 50 U/ml penicillin and 0.05 mg/ml 
streptomycin) at 37°C under 5% CO2. The tissue fragments were then agitated and cells 
were isolated and cultured as per [20].  On the seventh day after isolation, cells were 
treated with either PPARδ agonist (GW501516), PPARγ agonist (Rosiglitazone), LXR 
agonist (GW3965), RXR agonist (SR11237), or control (DMSO) all at concentrations of 
1 µM for 72 hours. 
4.3.2 RNA extraction, purification and qPCR 
Total RNA was isolated from cells using TRIzol® (Invitrogen). Cells were first lysed in  
TRIzol® reagent, phases were separated using chloroform (20%), and supernatant was 
removed. RNA was precipitated using 100% isopropanol (0.5%) and RNA was washed 
using 70% ethanol followed by air-dry and resuspension in RNAse free water, as per 
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manufacturer’s instructions. RNA was quantified using a Nanodrop 2000 
spectrophotometer. RNA integrity was confirmed with Aligent 2100 BioAnalyzer Data 
Review Software (Wilmington, DE) at the London Regional Genomics Centre and RNA 
samples with RNA integrity number (RIN) values greater than 8 were used for 
microarray analysis.  
Real-time PCR (qPCR) was performed as per [17]. In brief, qPCR was performed using a 
One-Step RT qPCR Master Mix kit and TaqMan Gene Expression Assays (Applied 
Biosystems), with 40 cycles on an ABI Prism 7900HT sequence detector (PerkinElmer), 
or on a Bio-Rad CFX384 RT-PCR system with 15 µl reaction volumes of iQ SYBR 
Green Supermix (Biorad) with diluted cDNA equivalent to 200 ng of input RNA per 
reaction, as well as 25 µM forward and reverse primers[21]. Probes for 
Acan(Mm00545794_m1), Actb (Mm02619580_g1), Adamts4(Mm00556068_m1), 
Adamts5 (Mm00478620_m1), Angptl4(Mm00480431_m1), Col2a1 (Mm01309565_m1), 
Fabp3(Mm02342495_m1), Fabp4(Mm00445878_m1), LPL(Mm00434764_m1), Mmp2 
(Mm00439498_m1), Mmp3 (Mm00440295_m1), Mmp13(Mm00439491_m1), 
Pdk4(Mm01166879_m1), Sox9 (Mm00448840_m1) were purchased from Life 
Technologies. Gene expression was normalized relative to ActB. Relative gene 
expression was calculated using the ΔΔCt  method [22] as described [23].  Statistical 
analysis was conducted using GraphPad Prism 6.0. Values were transformed, and a one 
way analysis of variance (ANOVA) was performed followed by Tukey’s multiple 
comparisons tests.  
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4.3.3 Microarray and Data Analysis 
Total RNA (200 ng per sample) was subject to 2 rounds of amplification followed by 
labeling and hybridization to Affymetrix GeneChip® Mouse Gene 2.0 ST Array 
containing 35,240 probes at the London Regional Genomics Centre (London, Ontario, 
Canada) as described [24]. Three independent cell and RNA isolations were used for each 
treatment. Probe data was analyzed, and gene level, ANOVA p-values and fold changes 
were determined using Partek Genomics Suite v6.6. Genes with at least 1.5-fold change, 
with p<0.05 were considered significant and used for subsequent analyses. The complete 
array data set has been made publicly available through Gene Expression Omnibus 
(GEO).  The Venn diagrams were created using the online plotting tool Venny 2.0.1[25]. 
Gene Ontology biological processes were classified through GO consortium available at 
geneontology.org. Biological processes identified with more than 3 genes involved were 
included in the table. 
4.3.4 Cell Lipid Mass  
IMACs were isolated, cultured, and treated with nuclear receptor agonists as described 
above. At the 72 hour time point, cells were washed with 0.2% BSA in phosphate-
buffered saline (PBS), followed by 3 washes in PBS. Lipids were extracted using 3:2 
hexane:isopropanol solvent and pooled. Hexane:isopropanol solvents were evaporated to 
dryness under N2 and resuspended in 1.4ml of chloroform-triton (0.5% triton v/v). 
Solvent was re-evaporated, and lipids were re-solubilized in 350 µl water. Two 50 µl 
aliquots were used per sample to determine total cholesterol (TC), free cholesterol (FC), 
and triglyceride (TG) mass , spectrophotometrically as per [26]. Cholesteryl esters (CE) 
were calculated by subtracting FC from TC. Proteins were extracted using 0.2 NaOH 
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overnight incubation to digest chondrocytes and quantified using a standard BCA protein 
assay (Pierce, Thermo Fisher Scientific). All cell lipid measures reported are standardized 
to mg of cell protein. Values were normalized relative to vehicle control DMSO, and 
statistical analyses were performed using GraphPad Prism 6.0. Values were transformed, 
and a one-way analysis of variance (ANOVA) was performed followed by Tukey’s 
multiple comparisons tests. 
4.3.5 Animals and Surgery 
All animal experiments were approved by the Animal Use Subcommittee at The 
University of Western Ontario and were conducted in accordance with the guidelines 
from the Canadian Council on Animal Care. Mice were group housed (6 mice per cage) 
in colony cages, on a standard 12h light/dark cycle with free access to standard mouse 
chow, water, and running wheels. Surgical destabilization of the medial meniscus 
(DMM) or SHAM surgery was performed on 12 week old C57/bl6 male mice (N=9 per 
group), as described in [14]. Mice were euthanized at 10 weeks post-surgery for 
preparation of paraffin sections, and subsequent histological analysis. Another cohort of 
20 week old male cartilage specific Ppard knockout mice and wild-type littermate 
controls underwent DMM surgery (N=5 per group) and were harvested for histological 
analyses 8 weeks later as in [14].  Paraffin sections from these studies were employed to 
evaluate the presence of Thioredoxin Interacting Protein (Txnip). 
4.3.6 Immunohistochemistry 
Immunohistochemistry was performed on frontal sections of paraffin embedded knee 
joints as described[27]. Txnip rabbit polyclonal antibody was purchased from proteintech 
(18243-1-AP). Slides without primary antibody were used as controls, antigen retrieval 
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was performed in 0.1% Triton in H20, primary antibody was used at a concentration of 
1:300.  
4.4 Results 
4.4.1 Global changes in chondrocyte gene expression in response 
to nuclear receptor agonist treatment 
We have previously reported that treatment of articular chondrocytes with the PPARδ 
agonist GW501516 results in increased gene expression of matrix-degrading enzymes, 
and robust fatty-acid oxidation. We have also determined that treatment of embryonic 
tibiae with the LXR agonist GW3965 suppresses chondrocyte hypertrophy[14, 17]. 
Identifying which genes are responsible for these phenotypes, and how they interact with 
each other, is key to understanding signaling pathways responsible for joint homeostasis 
and the prevention of osteoarthritis. We first examined global changes in chondrocyte 
gene expression in response to 1µM treatment with LXR agonist GW3965, RXR agonist 
SR11237, PPARδ agonist GSK501516, or PPARγ agonist Rosiglitazone. RNA was 
isolated from IMACs cultured with agonists for 72 hours, then hybridized to Affymetrix 
microarrays representing the mouse genome.  
We compiled a list of genes changed by more than 1.5 fold (refer to supplementary data 
for full list). LXR agonism significantly altered 128 genes (97 upregulated, 31 
downregulated), RXR agonism differentially regulated a total of 108 genes (67 
upregulated, 41 downregulated), PPARδ agonism induced changes in 58 genes (48 
upregulated, 10 downregulated), while PPARγ agonism changed 32 genes (29 
upregulated, 3 downregulated). The most robust and significantly upregulated and 
downregulated genes after nuclear receptor agonist treatment are shown in Figure 4-1. 
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LXR induced ATP binding cassette transporter subfamily A member 1 (Abca1), Stearoyl 
CoA desaturase 1 (Scd1), Insulin induced gene 1 (Insig1), ATP binding cassette 
transporter 
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Figure 4-1 Microarray analyses of nuclear receptor agonist effects on chondrocyte 
gene expression 
 Microarray analysis of RNA isolated from immature murine articular chondrocytes 
treated for 72 hours with 1µM LXR agonist GW3965 (A), RXR agonist SR11237 (B), 
PPARδ agonist GSK501516 (C), or PPARγ agonist Rosiglitazone (D). The most highly 
upregulated and downregulated genes are shown with fold change relative to vehicle 
control DMSO (1µM). 
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subfamily G member 1(Abcg1), Fatty acid desaturase 2 (Fads2), and downregulated 
Pleiotrophin (Ptn), Dermatopontin (Dpt), Alpha-2-macroglobulin (A2m), Thioredoxin 
interacting protein (Txnip), and Cpm (carboxypeptidase) (Fig. 1A). Activation of RXR, 
the heterodimeric partner for LXR, PPARδ and PPARγ, significantly upregulated 
Angiopoietin like 4 (Angptl4), Abca1, Fatty-acid binding protein 4 (Fabp4), Scd1 and 
Complement factor H (Cph) (Fig. 4-1B). Conversely, RXR significantly reduced 
expression of Six transmembrane epithelial antigen of prostate family member four 
(Steap4) (also known as Tumor necrosis alpha inducing protein 9), Ptn, Dpt, C1q and 
tumor necrosis factor related protein 3 (C1qtnf3) (Fig. 4-1B). PPARδ significantly 
induced Pyruvate dehydrogenase kinase isoenzyme 4 (Pdk4), Angptl4, Uncoupling 
protein 2 (Ucp2), 3-hydroxy 3-methylglutaryl CoA synthase 2, Acyl CoA thioesterase 1 
(Acot1), and significantly downregulated Protein phosphatase Mg2+/Mn2+ dependent 1K 
(Ppm1K), Glutathione S-transferase A 4 (Gsta4), Zinc finger protein 455 (Zfp455), 
Angiopoietin like 7 (Angptl7), and 3 Hydroxybutyrate dehydrogenase type 1 (Bdh1) (Fig. 
4-1C). Lastly, PPARγ agonism upregulated Fabp4, CD36 molecule (CD36), Cell death 
inducing DFFA like effector C (Cidec), Glycerol 3 Phosphate Dehydrogenase 1 (Gpd1) 
and Adiponectin C1Q and collagen domain containing (Adipoq), Carbonic anhydrase 3 
(Car3) and Lipoprotein lipase (Lpl) and downregulated predicted gene 17146 
(Gm17146), Zinc finger protein 600 (Zfp600), microRNA 186 (Mir186) (Fig. 4-1D). 
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4.4.2 Nuclear Receptors share common gene targets in 
chondrocytes 
Comparison of gene expression profiles induced by various nuclear receptor agonists 
revealed several common hits. We therefore decided to evaluate shared functional roles 
by identifying similar biological processes through Gene Ontology. Table 4-1 indicates 
the biological processes regulated by agonist treatment for each nuclear receptor, 
common processes are highlighted with the same colour. Both LXR and RXR agonism 
altered cholesterol biosynthetic processes, while LXR and PPARγ regulated triglyceride 
metabolism, and RXR and PPARγ increased metabolic processes in chondrocytes. In 
order to compare relationships between nuclear receptor agonist treatments, we created a 
Venn diagram to illustrate the number of genes induced by multiple receptors (Figure 4-
2). The two genes upregulated by all four nuclear receptor agonists were Pdk4 and 
Angptl4. Pdk4 functions as an inhibitor of the pyruvate dehydrogenase complex. Thus it 
plays a key regulatory role in shifting energy utilization from glycolytic to fatty-acid 
metabolism in the cell[28]. Angptl4 is a well known direct target of PPARs that is 
upregulated by hypoxia, and has been characterized as an adipocytokine[29]. It has also 
been identified as a potential pro-angiogenic mediator of arthritis, is involved in ECM 
remodeling, and is upregulated in the cartilage of RA and OA patients[30-32]. Since 
PPARδ has opposite effects on OA progression than PPARγ and LXR, we were also 
interested in genes showing opposite responses to the respective agonists. However, the 
only gene that was differentially regulated greater than 1.5 fold between any of the 
treatments was Txnip, which encodes the Thioredoxin interacting protein. Txnip inhibits 
Thioredoxin and contributes to ER stress, inflammasome activation, and the 
accumulation of reactive oxygen species (ROS)[33]. This gene was upregulated by 
124 
 
PPARδ agonist GW501516 and downregulated by LXR agonist GW3965 treatment. 
Based on the common genes identified, we next validated changes in the expression of 
these genes by qPCR. 
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Table 4-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biological processes regulated by nuclear receptor agonists as indicated by Gene 
Ontology (GO) Bioinformatics Analysis. Commonly regulated processes between 
treatments are indicated by the same colour. 
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Figure 4-2 Comparison of nuclear receptor agonist effects on chondrocyte gene 
expression 
Comparison of all genes regulated by the four different nuclear receptor agonist 
treatments on chondrocytes demonstrate that 2 genes are commonly regulated by all four 
nuclear receptors. 9 genes are commonly regulated by LXR, PPARδ, and RXR, while 4 
genes are commonly regulated by LXR, PPARδ and PPARγ. 3 genes are regulated by 
LXR, PPARγ, and RXR, and 2 genes are commonly regulated by PPARδ, PPARγ, and 
RXR. 
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4.4.3 LXR, RXR and PPAR agonism promote changes in genes 
involved in ECM homeostasis and chondrocyte metabolism 
Genes induced in the microarray were primarily metabolic, or involved in extracellular 
matrix component production and turnover. We chose to validate a subset of these genes 
which were shared between nuclear receptor agonist treatments. Aggrecan and Fibrillin 2 
are extracellular matrix proteins encoded by the Acan and Fbn2 genes. In concert with 
our microarray results, gene expression of Acan was significantly lower than vehicle 
control (DMSO) with RXR agonist treatment. Similarly, both LXR and RXR agonism 
significantly lowered gene expression of Fbn2 (Figure 4-3). Gene expression of Collagen 
2 (Col2a1) remained unchanged in response to any of the treatments. We also validated 
proteases that were changed by some of the nuclear receptor agonists, and accordingly 
found that gene expression of Adamts4, Mmp2 and Mmp13 were significantly reduced by 
LXR agonism. Interestingly, RXR agonism decreased gene expression of Adamts4 while 
increasing that of Mmp13 (the primary collagenase of OA), implying a preferential 
pathway for ECM remodeling and degradation.  
LXR, RXR, and PPARs are involved in the regulation of metabolism in a number of 
tissues. In a previous study we showed that chondrocytes express functional PPARδ and 
are capable of responding to GW50516 stimulation with increased fatty acid 
oxidation[14]. All four nuclear receptor agonists induced strong metabolic effects. 
Angptl4 and Pdk4, the two common genes induced by all four nuclear receptors in the 
microarray, demonstrated a similar robust upregulation in qPCR validation (Figure 4-4).  
Abca1, Cidea, Lpl and Cpt1a were significantly increased by PPARδ, LXR and RXR 
agonist treatment. Gene expression of cytoskeletal fatty-acid transporter Fabp3 was 
significantly increased by PPARδ activation, while Gsta4, a gene encoding an enzyme 
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for cellular defense against reactive electrophiles, was significantly reduced by both 
PPARδ and RXR agonism[34].  
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Figure 4-3 Effects of nuclear receptor agonist treatments on extracellular matrix 
gene expression in chondrocytes 
IMACs were incubated for 72 hours with 1µM DMSO (vehicle control), PPARδ agonist 
GW501516, PPARγ agonist Rosiglitazone, LXR agonist GW3965, or RXR agonist 
SR11237. (A) Relative gene expression of Acan gene is significantly reduced by 
treatment with the RXR agonist. (B, C) Relative gene expression of Adamts4 and Fbn2 
are significantly reduced by LXR and RXR agonist treatment. (D, E) Relative gene 
expression of matrix metalloproteinases Mmp2 and Mmp13 is decreased by LXR agonist 
treatment, while gene expression of Mmp13 is significantly elevated by RXR agonist 
treatment. (F) Col2a1 gene expression remains unchanged by all treatments.  Values 
represented are the mean ± SEM of ≥ 3 independent cell isolations. *= p<0.05. 
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Figure 4-4 Effects of nuclear receptor agonist treatment on metabolic gene 
expression in chondrocytes 
IMACs were incubated for 72 hours with 1µM DMSO (vehicle control), PPARδ agonist 
GW501516, PPARγ agonist Rosiglitazone, LXR agonist GW3965, or RXR agonist 
SR11237. (A,C,D,H) Relative gene expression of Abca1, Cidea, Cpt1a and Lpl is 
significantly increased by PPARδ, LXR and RXR treatments. (B,F) Relative gene 
expression of Angptl4 and Pdk4 is elevated by all four treatments. (E) Fabp3 gene 
expression is significantly upregulated by PPARδ agonism. (G) RXR and PPARδ 
treatment significantly decrease relative gene expression of Gsta4. Values represented are 
the mean ± SEM of ≥ 3 independent cell isolations. *p<0.05. 
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4.4.4 Increased expression of Thioredoxin binding protein in 
osteoarthritic cartilage 
Txnip plays an important regulatory role in mediating oxidative stress and inflammation 
in a number of tissues[33]. Txnip was the only gene differentially regulated between 
nuclear receptor agonists. LXR agonist treatment downregulated gene expression, while 
PPARδ highly induced Txnip. These patterns observed in microarray analyses were 
validated by qPCR, where PPARδ agonism significantly increased gene expression of 
Txnip while LXR agonist-treated cells demonstrated trends toward decreased gene 
expression, and RXR and PPARγ agonism showed no change (Figure 4-5a). 
Immunohistochemistry for TXNIP was performed on frontal sections of mice 8 and 10 
weeks post DMM surgery (Figure 4-5b,c). Wild-type mice 10 weeks post surgery had 
increased numbers of positively stained chondrocytes compared to mice that underwent 
SHAM surgery. To validate the effects of PPARδ on Txnip expression, we compared 
protein expression in cartilage-specific Ppard KO mice and wild-type littermates 8 weeks 
after DMM surgery. Wild-type mice demonstrated increased staining for Txnip, 
particularly in areas of osteophyte growth at joint margins, whereas both sham-operated 
control mice and KO mice after either surgery showed little to no staining. The increase 
of Txnip expression in the process of OA implies an imbalance in regulatory processes 
governing oxidative stress and inflammation, potentially linking changes in metabolism 
to osteoarthritic changes. 
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(A) IMACs were incubated for 72 hours with 1µM DMSO (vehicle control), PPARδ 
agonist GW501516, PPARγ agonist Rosiglitazone, LXR agonist GW3965, or RXR 
agonist SR11237. PPARδ treatment significantly increased gene expression of Txnip. 
Values represented are the mean ± SEM of ≥ 3 independent cell isolations. *p<0.05. (B) 
Immunohistochemistry (IHC) for Txnip demonstrates increased cellular staining in the 
cartilage of WT DMM mice 10 weeks post-surgery relative to SHAM mice. (C) IHC for 
Txnip in cartilage-specific Ppard KO mice vs WT littermate controls 8 weeks post DMM 
surgery. Ppard KO mice display less staining than WT mice with greater OA severity. 
No Primary 
Figure 4-5 Effects of nuclear receptor agonist treatment on Txnip gene expression 
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4.4.5 Changes in gene expression correspond with functional 
changes in chondrocyte lipid profile  
In light of the number of genes involved in lipid metabolism that were identified in our 
gene expression analyses, we assessed neutral lipid and cholesterol accumulation in 
chondrocytes. Using the same nuclear receptor agonist treatment protocols, we harvested 
IMACs for cellular lipid mass assays. These assays allowed us to directly quantify 
triglycerides and cholesterol in vitro. There were significant changes in cell triglycerides, 
but not total cholesterol, free cholesterol or cholesteryl esters (Figure 4-6). These data 
suggest that changes in lipid metabolism upon agonist treatment are likely related to 
lipogenesis and fatty acid oxidation, rather than cholesterol transport or accumulation. In 
particular, triglycerides were significantly decreased with PPARδ agonist treatment, and 
were significantly increased with LXR, PPARγ and RXR agonism.  These changes are 
consistent with the known effects of activation of these nuclear receptors on triglyceride 
metabolism in other cell types and suggest that PPARδ may have an opposing functional 
role in lipid metabolism in chondrocytes relative to the other nuclear receptors examined 
here[35]. 
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Figure 4-6 Quantification of cellular lipid mass 
IMACs were incubated for 72 hours with 1µM DMSO (vehicle control), PPARδ agonist 
GW501516, PPARγ agonist Rosiglitazone, LXR agonist GW3965, or RXR agonist 
SR11237.  Lipids were extracted, isolated and mass was measured 
spectrophotometrically. Proteins were isolated and quantified using BCA. Measurements 
are reported relative to mg of cell protein. (A) Cell triglycerides (µg) are significantly 
elevated by PPARγ, LXR, and RXR treatment, and are significantly decreased by PPARδ 
agonism. (B,C,D) Total cholesterol, free cholesterol, and cholesterol ester remain 
unchanged after nuclear receptor agonist treatment. Values represented are the mean ± 
SEM of ≥ 5 independent cell isolations. *p<0.05.   
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4.5 Discussion 
This is amongst the first studies to examine changes in global gene expression in 
chondrocytes after nuclear receptor agonist treatment paired with concurrent functional 
analysis. It provides compelling evidence that nuclear receptors are involved with early 
changes in cell metabolism that can influence deleterious changes in cell phenotype 
leading to the progression of OA. Nuclear receptors have been increasingly linked to the 
progression of OA. We have previously established the degenerative changes promoted 
by PPARδ agonism in cartilage, as well as the beneficial and necessary role of PPARγ in 
cartilage[14, 15]. We and others have characterized the protective role of LXR in 
osteoarthritis [17, 36, 37]. However, in order to establish how or whether these ligand-
activated receptors are feasible therapeutic targets we must examine what molecular 
changes cause the phenotypic changes characteristic of OA. 
We used IMACs treated with LXR, RXR, PPARγ or PPARδ agonists for 72 hours. 
Immature murine articular chondrocytes provide a large number of cells for analyses on 
fully differentiated primary chondrocytes while minimizing dedifferentiation [38]. 
Microarray analyses of IMACs revealed changes in metabolic and ECM genes in 
response to these agonists, changes which were largely confirmed by qPCR. Agonism of 
RXR decreased gene expression of the major ECM component aggrecan, and increased 
the expression of ECM protease Mmp13, while LXR agonism decreased the gene 
expression of proteases Adamts4, Mmp2, and Mmp13.  Of particular interest were the 
increases in expression of genes involved in lipid metabolism, since they showed greater 
induction than those regulating ECM turnover. Amongst these genes, two were induced 
by all four agonists, Pdk4 and Angptl4, suggesting that they might play central roles in 
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cartilage metabolism. Interestingly, in an earlier study we had also demonstrated 
increased expression of Pdk4 in response to dexamethasone, a ligand for the 
glucocorticoid receptor which is another member of the nuclear receptor family[39].  
Functional evaluation of lipid metabolism using cellular lipid mass assays demonstrated a 
significant decrease in triglycerides after PPARδ agonist treatment. Conversely, 
triglycerides were significantly increased with PPARγ, LXR, and RXR agonists. This is 
not surprising as PPARγ can often act antagonistically to PPARδ with regard to 
lipogenesis [40], while LXR mediates fatty acid biosynthesis through activation of genes 
such as Srebf1, Fasn, and Scd1 which corroborate our data (see supplementary)[41, 42]. 
Quantification of cell lipids in vitro is advantageous because it permits us to directly 
measure the amount of lipid being stored in chondrocytes. This enables us to assess 
differences in some aspects of lipid metabolism between treatments. In fact, it is plausible 
that the dysregulation in lipid metabolism that we observed could initiate metabolic 
changes in the cell that eventually lead to apoptosis, inflammation, or changes in cell 
behaviour such as synthesis of catabolic factors. It has been shown that there is increased 
lipid deposition in osteoarthritic cartilage, but also that increased reactive oxygen species 
(ROS) can cause lipid peroxidation, which in turn could cause oxidative stress resulting 
in degenerative changes to the matrix through oxidation of collagen II[6, 43].  
In addition to dysregulation of cell lipids, we also see significantly decreased Gsta4 
expression after PPARδ or RXR agonist treatment. The encoded enzyme Glutathione S-
transferase A 4 protects against HNE (4 Hydroxynonal)-induced damage in chondrocytes. 
HNE is an extremely reactive aldehyde produced from ROS and lipid peroxidation, and is 
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increased in synovial fluid from OA patients[42]. HNE can also post-transcriptionally 
modify Collagen 2 and MMP13 to induce degradative changes in cartilage. On the other 
hand, decreased levels of GSTA4 are present in human OA cartilage, making cartilage 
more susceptible to damage [34]. 
One gene of particular interest, Txnip (thioredoxin interacting protein) was highly 
induced by PPARδ agonism, but appeared repressed by LXR agonism, in agreement with 
the opposing effects of these nuclear receptors on OA progression. Thioredoxin is an 
important antioxidant, but binding of Txnip to thioredoxin inhibits its ability to scavenge 
for ROS[44].  In our study, we demonstrate increased gene expression of Txnip after 
PPARδ agonism in chondrocytes. We also show that cartilage-specific Ppard knockout 
mice that are protected against cartilage degeneration in OA have decreased Txnip 
staining after DMM surgery. In contrast, control mice have increased staining for Txnip 8 
and 10 weeks post-surgery when compared to SHAM-operated mice. A similar effect has 
previously been demonstrated in other tissues where silencing Txnip abrogated palmitate 
induced inflammasome activation and proapoptotic activity in retinal endothelial 
cells[45]. Additionally, Txnip has been shown to link oxidative stress and inflammation, 
and it can directly activate NF-kB and downstream inflammatory cytokines[45]. In 
chondrocytes, recent work has shown that Redd1 can form a complex with Txnip to 
regulate autophagy[46].  Taken altogether, these data help to form a cohesive picture of 
how changes in cell metabolism could influence the development of early osteoarthritis. 
Nuclear receptos appear to play a key role in these processes by regulating the expression 
of central players such as Txnip and Gsta4.  
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Current treatment strategies for OA are largely ineffective or inconclusive. It is possible 
that we are missing a critical temporal period during which chondrocyte homeostasis is 
disrupted, later leading to matrix degeneration. Recent evidence demonstrates that 
nuclear receptors are key regulators of OA pathogenesis, and the data presented here 
suggests that their primary targets are metabolic regulation. Metabolic deregulation, in 
turn, can trigger events leading to oxidative stress and inflammation, protease activation, 
and ultimately cartilage degeneration. Targeting these critical processes could be a 
promising avenue for treatments that alter disease progression. 
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Chapter 5  
5 Discussion 
5.1 Overview 
The overall objective of my thesis was to characterize the role of the nuclear receptor 
PPARδ in osteoarthritis (OA). Our laboratory first identified the PPARs as potential 
targets in OA through microarray studies comparing cartilage from rats with surgically 
induced OA to SHAM operated rats[1].  Subsequently, our group investigated PPARγ 
and demonstrated that it was necessary for cartilage homeostasis; cartilage-specific 
depletion of PPARγ either during skeletal development or in adult tissue is severely 
debilitating[2, 3]. Our laboratory next decided to investigate the role of PPARδ in-vitro, 
since these two nuclear receptors can have either opposing or complementary context-
dependent actions[4-6]. We found that PPARδ agonism by synthetic agonist GW501516 
results in significant increases in gene expression of matrix degrading proteases (Mmp 2, 
Mmp3, Adamts2, Adamts5) in mouse primary chondrocytes. Similarly, GW501516 
treatment of murine joint explants resulted in glycosaminoglycan (GAG) loss and an OA-
like phenotype. This data indicated a strong catabolic role for PPARδ in cartilage and 
provided the rationale for investigation of this target as a mediator of OA. 
The first study in my thesis investigates the role of PPARδ in OA. It built upon the in-
vitro work, and quantitated GAG loss in cartilage explants through a dimethylmethylene 
blue binding (DMMB) assay. This assay revealed that a significant number of GAGs are 
released from the joint after treatment with GW501516 and cemented the theory that 
PPARδ has catabolic effects in the joint. We believed that if this nuclear receptor’s 
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activity was destructive in the joint, then inhibiting it could attenuate some of these 
detrimental effects. Therefore, I generated a cartilage specific Ppard knock-out mouse to 
study the effects of PPARδ inactivation in skeletal development and osteoarthritis. Mice 
with conditional (‘floxed’) Ppard alleles (Ppardfl/fl) were bred to mice expressing Cre 
recombinase under the control of the Collagen 2 promoter. The mice were born in normal 
Mendelian ratios with no obvious defects. I examined skeletal development through 
analysis of gross skeletal morphology, and measurement of anatomical markers of the 
growth plate and long bones at time points of p0, p10, p21, and 5 months of age. These 
mice displayed no deformities in gross morphology, and had similar cellular organization 
and zonal lengths of growth plate cartilage as well as overall long bone length. As there 
were no congenital defects affecting anatomical or mechanical factors that predisposed 
these mice to OA development, we next surgically induced OA in mice at 20 weeks of 
age through a destabilization of medial meniscus surgery (DMM). This surgery is a 
widely used and accepted method for inducing secondary OA that develops gradually in 
the medial tibial plateau of mice[7-9]. 8 weeks post-surgery we compared the WT to KO 
mice through OARSI histopathology scoring and immunohistochemistry for cartilage 
breakdown products. I discovered that while WT mice had moderate-severe cartilage 
breakdown in the medial tibial plateau and medial femoral condyles of the knee, as 
expected, the Ppard KO mice showed much less damage. Cartilage was significantly 
protected from the progression of OA. This was recapitulated in my staining for cartilage 
neoepitopes, which demonstrated increased staining for these products in the lesions of 
WT mice after DMM surgery, while the KO mouse cartilage had little to no staining[10].  
I concluded that genetic PPARδ inhibition in cartilage was protective in post-trauamtic 
146 
 
OA. I suspected this protective effect was in part due to a reduction of fatty acid 
oxidation (and resulting oxidative stress) seen in our early studies, since cartilage 
primarily metabolizes energy through glycolytic pathways.   
Next, I investigated pharmacological inhibition of PPARδ in post-traumatic OA in rats. 
The genetic model provided a strong foundation for our studies, but in order for this 
evidence to be translated into a useful therapeutic strategy, we needed to find a treatment. 
I administered PPARδ inhibitors (GSK0660, GSK3787), or vehicle control DMSO after 
surgical induction of OA through anterior cruciate ligament transection (ALCT) and 
partial medial meniscectomy (PMMx). These drugs were administered daily (6 days a 
week) for four weeks. Concurrently, behavioural assessments were also conducted 
weekly on rats to evaluate behaviour modifications associated with pain. Changes in 
pain-related behaviour were observed in rats who had surgically induced OA, but no 
PPARδ drug treatment. These rats rested more and performed less vertical activity. They 
also redistributed their limb loads by compensating with the contralateral limb. All these 
changes were blocked by the PPARδ inhibitors. I also investigated structural pathology 
through toluidine blue staining paired with OARSI scoring. I discovered that rats without 
drug treatment had severe cartilage loss and substantial bone remodeling. In contrast,  rats 
who were administered PPARδ inhibitors experienced focal fibrillation, cartilage 
shearing and bone remodeling. When semi-quantitatively assessing these pathologies, 
cartilage degeneration and subchondral bone damage after surgical induction of OA was 
significantly different than SHAM operated rats in the DMSO group, while PPARδ 
inhibitor treated rats fell somewhere in the middle. It may be necessary to find other 
measures and time points to quantitate damage, or to increase the N, to elucidate whether 
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there are substantial differences between treatment groups. I concluded that PPARδ 
inhibition results in protection from pain-related behaviours after surgical induction of 
PTOA in rats, and this may be in part related to milder structural progression of OA.  
Lastly, I identified novel gene targets for PPARδ in chondrocytes. We conducted 
microarray studies paired with real-time PCR validation on immature murine articular 
chondrocytes treated with PPARδ agonist GW501516, PPARγ agonist Rosiglitazone, 
LXR agonist GW3965 and RXR agonist SR11237. These studies revealed that genes 
induced after treatment were largely metabolic in nature, primarily affecting lipid 
metabolism. Genes involved in oxidative stress and extracellular matrix turnover were 
also identified. Next, functional cellular lipid assays were performed to quantify cellular 
triglycerides, total cholesterol, free cholesterol and cholesterol esters. I observed a 
significant decrease in triglycerides after treatment with GW501516. This result, paired 
with our earlier in-vitro investigations, implied that chondrocytes were undergoing 
significant fatty-acid oxidation in response to PPARδ stimulation. It is also probable that 
this shift in metabolic pathway could cause an increase in oxidative stress; and so we 
investigated one of the genes significantly induced in our arrays, Txnip. This gene 
encodes thioredoxin interacting protein, which binds and inhibits thioredoxin - a potent 
antioxidant. We investigated the presence of this protein in OA by performing 
immunohistochemistry on knee sections from mice who underwent surgical induction of 
OA through DMM. 10 weeks post-surgery TXNIP was present and intensely stained 
damaged cartilage, whereas there was little to no staining in the SHAM operated mice. 
We also wondered whether this could be a potential mechanism underlying PPARδ ‘s 
effects in OA, so we stained Ppard KO mice and WT littermate controls 8 weeks post-
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DMM surgery with the same antibody. We found increased staining in WT mice that had 
more severe damage, with prominent staining at joint margins and in osteophytes. In 
contrast, the Ppard KO mice that were protected from OA progression had little to no 
staining. From this I concluded that early OA changes caused by PPARδ may be 
metabolic, and could be due to increased oxidative stress paired with lipid peroxidation. 
Overall, these data demonstrate a significant role for PPARδ in the promotion of OA and 
establish PPARδ inhibitors as a potential therapeutic agent for structural pathology as 
well as pain-related behaviour. 
5.2 Contributions and Significance of Findings 
5.2.1 Contributions to the Field of Osteoarthritis 
In this thesis, I characterize for the first time the role of PPARδ in OA. This was 
accomplished through cartilage specific deletion of Ppard. In Chapter 2, I present work 
where I discovered that PPARδ did not contribute significantly to joint or cartilage 
development, in contrast to Pparg which is essential for skeletal development[2]. 
Additionally, PPARδ had never previously been examined in the context of PTOA. Here, 
I demonstrate that inactivation of PPARδ in cartilage is beneficial, and chondro-
protective after surgical induction of OA by DMM. Again this is in contrast to studies 
examining cartilage-specific deletion of Pparg which induces OA; indicating that these 
nuclear receptors have differential roles in both skeletal development and OA 
progression[3].Through these studies, I establish PPARδ as a potential therapeutic target 
in OA. 
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In Chapter 3, I draw upon my findings from the previous study indicating that genetic 
PPARδ inactivation attenuates disease progression in PTOA and translate this into a 
preclinical model using pharmacological inhibitors of PPARδ, to examine whether drug 
treatment will recapitulate this protective effect. Currently there are no drugs available 
that stop or delay disease progression in OA. In this study, I employed rat model paired 
with ACLT/ PMMx surgery to induce more rapidly progressing OA. This model is 
advantageous because it permits the evaluation of pharmacological agents in a shorter 
duration of time, and is commonly used and accepted[1, 11-13]. I discovered that rats 
treated with PPARδ inhibitors do not experience the same behavioural modifications 
indicative of pain after surgical induction of OA, as untreated rats. It also appears that the 
inhibitors could confer some protective effects in both the cartilage and subchondral 
bone, but this will need to be more thoroughly quantitatively assessed. In addition to 
directly assess the role of PPARδ, this study is among the first in the world to correlate 
changes in disease progression at a structural level with functional behavioural 
modification in a rat model. We build upon our own previous data validating the methods 
of behavioural testing (spontaneous locomotor activity and incapacitance testing) with 
histopathological progression of disease[14]. We also show that there may be a 
disconnect between significant effects of our PPARδ inhibitors on pain behaviour but not 
on structural progression, similar to how a portion of patients who have radiographic 
osteoarthritis are asymptomatic for pain[15]. However, this needs to be studied in more 
depth before we can reach firm conclusions. Further we are able to show similar effects 
(at least qualitatively) in two different animal animal models, strengthening the 
foundation for PPARδ’s potential as a feasible therapeutic target. 
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Chapter 4 identifies novel gene targets in chondrocytes after treatment with the PPARδ 
agonist GW501516. These genes are highly involved in lipid metabolism, and our studies 
demonstrate that these changes in gene induction are functionally executed by 
chondrocytes. It has previously been established that chondrocytes can store lipids, and 
lipid or cholesterol abnormalities can influence the progression of OA[16-18]. 
Commonly, OA studies use Oil-Red O staining to visualize lipid deposition[19-21]. Here 
we quantitate the amount of lipids being stored and secreted by chondrocytes, in-vitro. 
This is beneficial because it allows us to form a greater understanding of the changes 
occurring at a molecular level. We measure significantly less triglycerides in 
chondrocytes after PPARδ treatment. In our earlier studies, we had observed significant 
upregulation of beta-oxidation after treatment with the same PPARδ agonist. 
Cumulatively this indicates that chondrocytes respond to PPARδ by increasing their 
energy utilization from triglycerides. This is of interest since usually energy metabolism 
in chondrocytes is thought to be largely glycolytic[22, 23].   
In this study we also observed a significant decrease in gene expression for Gsta4, the 
gene that encodes Gluthathione s-transferase A 4, in response to PPARδ activation. 
Gluthathione s-transferase A 4 protects against HNE (4 hydroxynonal) induced damage 
in chondrocytes. HNE is produced from ROS and lipid peroxidation and increased in OA.  
It can post-transcriptionally modify the ECM and activate proteases to degrade the 
matrix. It is possible that the decreased levels of Gsta4 in combination with increased 
fatty acid oxidation in response to PPARδ activation causes severe oxidative stress and 
ultimately chondrocyte dysfunction. This stress can be further enhanced by increased 
levels of Txnip, since this gene is induced by the PPARδ agonist.  Increased presence of 
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TXNIP in OA cartilage in our mice supports this model and is indicative of increased 
oxidative stress and lipid peroxidation stemming from the dysregulation of lipid 
metabolism. Recently, another group also identified TXNIP as a regulator of autophagy 
in chondrocytes[24]. It is likely that an imbalance in regulatory processes mediating 
oxidative stress and inflammation promotes the OA phenotype that we observe (Figure 5-
1). 
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Figure 5-1 Schematic of PPARδ function in OA 
PPARδ activation in chondrocytes by lipid ligands increases gene expression of Txnip, 
and results in increased production of thioredoxin interacting protein (TXNIP) which 
promotes oxidative stress by binding to anti-oxidant thioredoxin. Unregulated oxidative 
stress can cause chondrocyte dysfunction and this process may be in part responsible for 
what we observe during OA. Knee provided by Dr. M. Pest 
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5.3 Limitations of Research 
5.3.1 Limitations in In-vitro Models 
It is important to note and carefully consider the limitations in the studies described in 
this thesis. Firstly, although the immature murine articular chondrocytes (IMACs) are 
advantageous in that they allow us to investigate interventions on fully differentiated 
chondrocytes, with minimal dedifferentiation into other cell types, they are still limited in 
their ability to reproduce an in-vivo environment[25, 26]. The joint is a functional unit, 
and the cartilage, synovium and subchondral bone all communicate with each other, and 
are necessary to each other’s functions. This in-vitro system lacks that feature, as well as 
normal mechanical stimulation. Even when examining the cartilage alone, chondrocytes 
plated in monolayer are not representative of cartilage tissue with its ECM, and different 
oxygen tensions throughout the tissue. Cells that normally interact with the matrix, 
instead interact with each other in culture, which subsequently can result in altered 
signaling[27, 28]. However, some of the mechanistic studies done here are almost 
impossible to do in-vivo, requiring the use of in-vitro surrogates with an awareness of 
their limitations. 
In our array studies, we investigated one time-point; 72 hours. Genes may be 
differentially induced at earlier and later time-points. Further we only used one 
concentration of agonist for each of the nuclear receptors. While the concentration of 
1µM was effective at inducing known target genes, different concentrations could have 
had a more potent effect on downstream target genes. Additionally, microarrays are not 
specific for direct gene targets. Chromatin Immunoprecipitation with subsequent DNA 
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sequencing (ChIP seq) would be ideally used to elucidate direct targets of PPARδ when 
appropriate antibodies become available – unfortunately, the lack of ChIP grade 
antibodies is a common problem in the nuclear receptor field. 
5.3.2 Limitations of In-Vivo Models 
In-vivo models enable us to evaluate interventions and gain valuable information about 
behaviour and pathophysiology but they also have substantial limitations. In Chapter 2, I 
generated a tissue specific knockout of Ppard. The Cre-driver used in this model was 
Col-2 Cre which has since been characterized to be not completely cartilage specific with 
recombination occurring in a portion of osteoblasts and other joint cells as well[29, 30]. 
This might be a difficult problem to overcome in light of the strong evidence for 
chondrocyte-osteoblast trans-differentiation; however, the use of an inducible Cre driver 
(e.g. Agggrecan CreER) and postnatal tamoxifen injection could minimize these 
concerns[29].  
In my study investigating the progression of PTOA with systemic treatment of PPARδ 
inhibitors one of the major limitations was the method of drug delivery, which was daily 
subcutaneous injections. Firstly, we do not know how much of the drug actually reaches 
the joint tissues and how long it stays there. They must penetrate through the synovial 
membrane or subchondral bone in order to reach the cartilage. A solution to this would be 
to give the drug intraarticular, however this is complicated in a rodent because the 
injection itself could risk damaging the joint. Additionally, systemic delivery could have 
long term detrimental consequences because PPARδ is broadly expressed in a number of 
tissues where it serves to regulate metabolism[6, 31]. 
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Both of the in-vivo studies only used one-time point, whereas early and late stage OA- 
particularly PTOA are quite different[32]. While PPARδ may have one effect at one time 
point, it may not act the same way at different stages of OA, with different levels of 
inflammation and mediators present. Therefore, it would be beneficial to characterize its 
effects at different time-points from early to late stage OA. Another common factor 
between these studies, is that they both employ rodent models. While these rodent models 
are economically efficient, and enable evaluation of disease progression and interventions 
over a shorter period of time, they do not fully recapitulate the biomechanics of human 
OA, as they are quadrupeds and have a tail. Rodents have growth plates that do not fuse 
as they become skeletally mature and their size limits tissue discrimination and 
availability. Larger animal studies, though also quadrupeds with tails, may be more 
beneficial for imaging studies due to their size, and also have more tissue for biochemical 
analyses, but they are far more costly, difficult to house and manage, and do not have the 
option for genetic modification[33]. Lastly, both in-vivo models only used male animals. 
It has been well documented in human studies that the incidence of OA, progression, and 
severity are greater in post-menopausal females, implying that sex-hormones could be 
responsible for chondroprotective effects in females[34]. It has also been demonstrated 
that male mice develop the most severe OA following surgical destabilization of the 
medial meniscus, followed by orchiectomized males, ovariectomized females and then 
female mice[35]. It would therefore be more encompassing to account for the effects of 
sexual dimorphism on OA progression by investigating both sexes. 
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5.4 Future Directions 
The foundation established by this thesis can be further expanded and built upon in 
several ways, some of which can directly address the limitations discussed above.  
Molecular studies could use RNA-sequencing to form a more complete picture of what is 
happening in chondrocytes after they are treated with the PPARδ  agonist. This would 
encompass non-coding RNAs as well as alternative splicing. Executing these studies in 
multiple tissue types including synovium and osteoblasts would add to its 
comprehensiveness. Moreover, additional shorter and longer time points would add 
important information. As mentioned above, if ChIP grade antibodies to PPARδ  become 
available, this technique would ideally complement RNA-sequencing to distinguish direct 
and indirect targets.  
As described earlier, the Col-2 Cre driver used in the transgenic mouse studies was not 
specific; to evaluate the role of PPARδ  in cartilage we could instead employ an aggrecan 
Cre driver which is more specific and temporally controlled[34]. However, as OA affects 
multiple tissue types, it would be equally important to evaluate the role of this candidate 
in other joint tissues such as bone by using an osteoblast-specific Cre driver such as one 
driven by the osteocalcin promoter[35]. 
In addition to examining multiple tissue types through transgenic mouse studies, it would 
be beneficial to investigate changes in bone mineral density, and subchondral plate 
thickness through MicroCT imaging after administration of PPARδ in a model of PTOA. 
Similarly, looking at changes in the synovium, such as inflammatory markers and 
synovial membrane thickness, would be helpful to obtain a more cohesive picture of 
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disease progression and to evaluate whether PPARδ inhibition was helpful or detrimental 
in one tissue versus another. The dorsal root ganglion demonstrates changes in 
innervation and macrophage infiltration during the progression of OA, and future studies 
could include these changes in their assessment[36], especially in light of the dis-connect 
between behavioral and structural outcomes seen in chapter 3. Next steps would also 
involve assessing outcomes at different stages of OA, early vs late, as well as the use 
local delivery combined with a vehicle that promotes long-term release, so inhibitors do 
not need to be administered every day. In addition, an increase in the number of animals 
tested in our rat model (chapter 3) will be required to examine whether the trend towards 
structural benefits of the PPARδ inhibitors reflects true beneficial effects. 
The in-vivo studies described here focus on post-traumatic osteoarthritis which is only 
representative of 12% of all OA cases[37]. Further studies should investigate primary 
age-associated osteoarthritis and metabolic OA.  Some of these studies are in progress in 
our laboratory already. PPARδ is an important regulator of metabolism in many tissues, 
and has promoted changes in metabolism in our own studies. Therefore it would be 
worthwhile to evaluate the role of PPARδ in high-fat diet induced OA, and in 
combination with OA promoting fatty acids. Lastly, it would also be important to 
evaluate differences in PPARδ expression and activity in human tissue samples from 
different sub-types of OA. This would add another dimension and potentially enhance our 
rationale for the continued investigation of this target. 
In conclusion, the data shown here suggest that PPARδ is an important promoter of post-
traumatic OA, possible through induction of lipid metabolism and associated oxidative 
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stress. Future studies will need to expand on these results to determine the relative 
importance of this player in OA, and to further evaluate its potential as therapeutic target.   
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